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 La tomographie par émission de positons (TEP) est une modalité d’imagerie nucléaire 
puissante, permettant des mesures fonctionnelles non-invasive dans les cellules, les animaux et 
les humains avec une haute sensibilité et résolution.  Les exosomes sont des vésicules 
extracellulaires de 30 à 120 nm qui peuvent transférer leur contenu cytoplasmique entre cellules, 
mais comprendre leurs cheminements in vivo reste un défi. Les hydrogels thermosensibles à base 
de chitosane ont été développés et sont sous optimisation pour diverses applications telles que 
l'embolisation des vaisseaux sanguins, l'administration de médicaments, l’'administration de 
lymphocytes et la réparation du cartilage et des disques intervertébraux. Il y a un besoin urgent 
de suivi in vivo à court terme pour évaluer la rétention des hydrogels et des exosomes. Le 
Hexadécyl-4- [18F]-fluorobenzoate ([18F]HFB) est un radiotraceur lipophile à longue chaîne qui 
est retenu dans les membranes cellulaires et les biomatériaux. Le but de ce travail était 
d'automatiser la radiosynthèse de [18F]HFB pour marquer des exosomes et des hydrogels. La 
radiosynthèse et la purification de [18F]HFB ont été réalisées en utilisant le synthétiseur de 
chimie commercial IBA Synthera®. [18F]HFB a été préparé via substitution du précurseur 
d’ammonium quaternaire par [18F]F-. Après une première purification via une cartouche C18, 
[18F]HFB a été élué avec de l'acétonitrile et purifié par HPLC. [18F]HFB a ensuite été reformulé 
dans une solution de DMSO (10%) après élimination du solvant HPLC sous azote, filtré et dilué 
dans une solution saline stérile. [18F]HFB a été obtenu en rendement radiochimique allant de 15 à 
45% (corrigé pour désintégration), en haute pureté radiochimique et chimique, et dans un temps 
de synthèse total de 60 minutes. Les exosomes n'ont pas été marqués avec succès. Cependant, les 
hydrogels de chitosane ont démontré un marquage élevé, avec une stabilité du complexe >90%, 
même après 8 heures d’incubation en solution saline. La TEP avec [18F]HFB d'exosomes et de 
biomatériaux présente une approche novatrice pour déterminer leur distribution in vivo.  
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Positron emission tomography (PET) is a powerful nuclear imaging modality allowing 
for non-invasive functional measures in cells, animals and humans with high sensitivity.  
Exosomes are 30-120 nm extracellular vesicles that can transfer their cytoplasmic contents 
between cells, however, understanding where exosomes traffic in the body remains a challenge. 
Chitosan-based thermosensitive hydrogels have been developed and are currently under 
optimization for various applications such as blood vessel embolization, drug delivery, 
lymphocyte delivery systems, and cartilage and intervertebral disc repair. There is an urgent need 
for in vivo, short term follow-up of such procedures to assess the retention of hydrogels and 
exosomes at the site of injection. Hexadecyl-4-[18F]fluorobenzoate ([18F]HFB) is a long chain 
lipophilic radiotracer that has been reported to be retained within cell membranes or 
biomaterials. The aim of this work was to automate the radiosynthesis of [18F]HFB for labeling 
exosomes and chitosan-based hydrogels. The radiosynthesis and purification of [18F]HFB was 
done using the commercial IBA Synthera® chemistry synthesiser with the R&D IFP-cassette and 
HPLC module. As previously reported, [18F]HFB was prepared by [18F]F- substitution of the 
trimethyl ammonium triflate precursor in DMSO. After removal of unreacted [18F]F- and DMSO 
via a C18 light cartridge, [18F]HFB was eluted with acetonitrile and purified by semi-prep C18 
HPLC. [18F]HFB was then reformulated in DMSO (10%) solution after removal of the HPLC 
solvent from the radioactive product peak under nitrogen, filtered, and diluted in sterile saline. 
[18F]HFB was obtained in radiochemical yield (isolated after HPLC and evaporation) ranging 
from 15 – 45% (decay-corrected), high radiochemical and chemical purities, and within a total 
synthesis time of 60 mins. Exosomes were not successfully labeled. However, high labeling 
efficiency was observed with the chitosan hydrogels displaying a stability >90%, even after 8 
hours incubation in saline. PET imaging with [18F]HFB of exosomes and biomaterials presents a 
novel approach to determining their in vivo distribution.  
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Chapter 1: Positron Emission Tomography and Radiochemistry 
1. Nuclear Imaging  
 
 Nuclear imaging is a branch of nuclear medicine that deals with the application and 
detection of decaying radioisotopes. Typically, a radiopharmaceutical is injected, inhaled or 
swallowed by a patient and the detection of the radioactive decay is done through either positron 
emission tomography (PET) or single photon emission computed tomography (SPECT) [6]. In 
clinical nuclear medicine, roughly 95% of radiopharmaceuticals are used for diagnostic 
purposes, with the remaining 5% employed for therapy [7]. Radiopharmaceuticals usually 
contain a radioisotope linked to a small amount of active ingredient, with the main purpose of 
obtaining an image or a measure of biological activity/biodistribution. Radiopharmaceuticals do 
not usually have any pharmacological activity as they are administered in extremely small 
concentrations and therefore do not display any dose-response relationships. PET and SPECT 
have the advantage of being highly sensitive imaging modalities with the total mass of tracer 
needed to create an image being in the nanogram range[8]. However, PET and SPECT offer 
lower spatial resolution, the minimum distance between two points in an image that can be 
detected by a scanner, as compared to X-ray, CT and MRI (Table 1.1). The lower resolution 
makes it difficult to visualize small details and limits the size of structures that can be accurately 
imaged [9], although the radiation exposure that results from a clinical FDG PET scan of a 
human is approximately half that for a whole-body diagnostic x-ray CT image [10]. Finally, 
compared to optical fluorescence and echography imaging, PET and SPECT have higher 
sensitivity [9].  Our discussion will focus on PET and the various aspects involved with PET 






1.1 Introduction to the PET concept  
 
PET is a nuclear imaging modality that has become the most powerful molecular imaging 
technique currently available for clinical and basic scientific use. In recent years, PET has seen 
an increase in clinical applications due to advances in instrumentation and synthetic chemistry, 
resulting in the development of high sensitivity PET scanners and a broad range of PET tracers 
[11]. PET allows for the quantitative assessment of numerous biological processes including 
perfusion, metabolism, protein expression and enzyme activity, in vivo, in a non-invasive manner 
[12]. PET works through the detection of gamma ray photons resulting from the annihilation 
between a positron emitted from a decaying radionuclide and an electron to construct a three-
dimensional image. PET tracers are predominantly developed through combining radionuclides 
(radioactive isotopes) with biologically active molecules to produce a radiolabeled probe that can 
image a biochemical pathway or receptor. The radionuclide undergoes beta-decay through the 
emission of a positron, which travels a short distance and undergoes an annihilation event with 
an electron. This produces two high-energy 511 keV photons that travel in opposite directions 
that are detected as a coincidence event (Figure 1.1) [6]. This allows for the quantification of 
radioisotope concentration and the construction of an image based on radiotracer distribution 
throughout the body [13].  
The variety of available PET tracers combined with advanced analytical methods 
supports the application of PET for the assessment of normal biological processes, changes in 
biological processes associated with disease formation and progression, and the ability to 
longitudinally monitor the response of healthy and diseased tissues to therapeutic intervention 
[12]. Furthermore, PET also sees applications throughout the drug discovery process to assess 






to drug exposure [8]. The ability for PET to image biodistribution will be of high importance for 
this work and will be discussed in more detail in chapters 2 (exosomes/biomaterials). 
1.2 Introduction to Radioactivity  
 
Radionuclides are most commonly produced artificially in a cyclotron or reactor (for 
PET) although some exist naturally. Radionuclides are unstable as they have excess energy due 
to an unsuitable ratio of neutrons to protons [6]. To become stable, this excess energy can be 
emitted from the nucleus as gamma radiation or through the emission of particles such as α 
particles, ß- particles, ß+ particles, electron capture and isomeric transition. Through the emission 
of energy or various particles, the unstable nuclide is said to have undergone a decay event, 
resulting in the production of a different nuclide which may be stable or remain unstable [6].  
 Positron decay occurs when a radionuclide is proton rich and neutron poor. The process 
involves the conversion of a proton into a neutron with the emission of a positron (ß+) and a 
neutrino (v). Positron decay leads to nuclear transmutation, whereby an atom of one chemical 
element is transformed into an atom of an element with an atomic number that is less by one 
unit. This is seen in Figure 1.2 where radioactive fluorine-18 ([18F]) undergoes decay primarily 
through positron emission (96.86%) and the remainder electron capture (the nucleus captures a 
nearby orbital electron) to form stable oxygen-18. In this case, the atomic number decreased by 1 
(9 to 8), whereas the mass number remained the same (18) [6]. PET makes use of positrons 
through the resultant process that occurs after decay. As the positron is emitted, it begins to lose 
kinetic energy by interaction with matter, and then with electrons of absorber atoms where it 
combines with an electron [7]. At this moment, both particles (electron and positron) are 






opposite directions (~ 180˚). The detection of the two opposite 511-keV photons in coincidence 
by detectors is the basis of PET [6].  
1.3 PET Imaging 
 
PET tracers are made up of a biologically active molecule and a short-lived positron-
emitting isotope. The most common radioisotopes utilized in PET are 15O, 13N, 11C and 18F, with 
18F having the longest half-life of 109.6 minutes (Table 1.2). The advantage of a longer half-life 
allows for more complex synthesis procedures, long PET imaging protocols, shipment of the 
PET tracer to offsite facilities without the infrastructure to produce PET isotopes and the ability 
to perform multiple patient scans from one production of tracer [7]. To produce PET tracers, a 
laboratory must be able to manufacture radioisotopes and combine these with precursor 
molecules to produce a final radiolabeled tracer under automated conditions.  
 PET radioisotopes are produced in a cyclotron; a cylinder-shaped high-vacuum chamber 
that combines a magnetic field and a radio-frequency system to produce an alternating electric 
field which is applied to accelerate particles to very high energies. These accelerated particles 
can in turn be utilized as projectiles to bombard stable elements loaded in a target to induce 
different types of nuclear reactions that lead to the production of radioactive elements [7].  Most 
medical cyclotrons are negative ion cyclotrons and accelerate negative hydrogen atoms (H-). 
These H- ions are accelerated in a circular path with increasing kinetic energy until they are 
stripped of two electrons to produce positive ions (protons) which are used to bombard a target. 
The proton is absorbed by the target nucleus causing a nuclear transformation which produces an 
unstable radioactive isotope (Table 1.2). For example, to produce [18F]F-, 18O enriched water is 
bombarded with 11 MeV protons, according to the nuclear reaction 18O (p, n)18F [6]:  






After radioisotope production, the radioisotope is transferred to a shielded hot cell to an 
automated synthesis module. Here, the radioisotope undergoes a chemical reaction with a 
precursor molecule to produce a PET tracer.  
 To detect annihilation photons, PET scanners utilize a circular ring of pairs of gamma ray 
detectors that works off the basis of coincidence detection of gamma photons. The detection of 
the gamma rays determines a line of response (LOR) along which the annihilation took place 
(Figure 1.3). A true coincidence event is determined by imposing an acceptance window on the 
time difference between detection of the two events (a few nanoseconds wide) which helps to 
filter out scattered or random coincidences [14]. The time of flight (TOF) PET technique is based 
off the measurement of time differences in the arrival of the two photons at the detectors and 
provides the probability the event occurred at a specific location along the LOR.  
 Block detectors are the most common type of detectors and they consist of a solid 
scintillation detectors coupled to a photomultiplier tube (PM), a linear amplifier, and a pulse 
height analyzer (PHA) [6]. A scintillation detector is employed to absorb the gamma ray and 
convert this into lower energy light photons. The light photons are then converted into an 
electrical pulse by the PM, amplified and analyzed by the PHA. A PHA is a device that sorts out 
photons of different energies and in the case of PET systems, the PHA is centered at 511 keV 
[6]. If the annihilation photons are registered as a coincidence event, mathematical tomographic 
image reconstruction algorithms transform the signal into an image that represents a slice 
through the object in the plane of the detector ring. Some image reconstruction algorithms that 
are currently in use with PET scanners include: filtered backprojections, expectation 






Modern PET scanners are often coupled with other imaging modalities such as CT or 
MRI. This helps physicians to compare the higher resolution CT or MRI images to the low-
resolution PET images to determine precise localization of anatomical structures before 
administering therapy. Furthermore, by combining PET and CT, it is possible to perform a CT 
transmission scan that can be implemented for attenuation correction for PET images, resulting 
in a more accurate image [6]. The CT scan creates a density map of the body that can be used to 
correct for the different absorption of photons through various tissues of the body. Another factor 
that helps to increase the quality of the images is to correct for the partial volume effect. The 
partial volume effect leads to a smearing of activity over a larger area than it occupies in a 
reconstructed image and this is due to the limitation in the spatial resolution of PET scans. A 
correction needs to be applied for overestimation or underestimation of activities in small 
structures to obtain better quality images [6].  
Many research efforts have been focused on maximizing the performance of PET scanners, 
which becomes more complicated when dealing with small animal imaging [12]. Small animal 
imaging (µPET) provides many advantages for completing translational research for 
understanding human diseases, however, size differences in organs and tissues between humans 
and small animals creates many challenges for µPET imaging. The human/mouse and human/rat 
mass ratios fall in the range of 2,500 to 3,750 and 250 to 375, respectively [12], which results in 
an approximate 10 times smaller volume in these small animals. Consequentially, to obtain the 
same quality of images in small animals as humans, the spatial resolution of µPET scanners 
would need to be improved by a factor of 10. Current PET scanners have a spatial resolution of 
approximately 6-8 mm and µPET scanners around 1-2.5 mm [15]. Furthermore, an important 






administered. In human studies, the amount of tracer being injected does not perturb any 
biological systems, however, this may not always be true for small animals due to their 
significantly smaller body weight.  
1.4 PET Tracers 
 
In theory, any biological molecule can be labeled with a radioisotope by direct 
substitution of a nonradioactive isotope, leading to a labeled compound with virtually identical 
biochemical properties to the native compound that can trace the target of interest without 
disturbing the system [8]. The range of targets available for PET imaging are essentially 
limitless, and can include, but is not limited to: specific receptors, second messenger systems, 
enzymes, proteins, metabolic pathways and perfusion. Once the target has been identified, there 
is the option of developing a new compound or opting to work with a known pharmaceutical. 
The advantages of working with an established pharmaceutical are that the pharmacological 
profile and toxicology are already known, which facilitates the approval process for human use 
by regulatory agencies such as Health Canada. Regardless of which radioisotope is utilized, it is 
important that the labeled compound maintain the biological and chemical properties of the 
native compound.  
Many factors need to be met for a PET tracer to succeed and this also depends on 
whether the target is saturable or nonsaturable. In general, the radiotracer should be present in a 
very low concentration so that it does not disturb the biological process under study and ideally 
only interact with one specific receptor or binding site, therefore minimizing non-specific 
binding. The radiotracer should also have a high target-to-background ratio, a fast clearance from 
plasma and resistance to metabolism for quantitative studies. If the radiotracer is metabolized by 






the results as the signal coming from the native molecule and the labeled metabolite could have 
different pharmacological binding profiles [12].  
From a radiochemists standpoint, the radiosynthesis should be simple, fast, reproducible, 
high-yielding, easy to purify and automate with a synthesizer. Automated synthesizer units 
(ASUs) are controlled by microprocessors and software programs to carry out the sequential 
physical and chemical steps to accomplish the entire synthesis of a radiotracer (synthesis and 
purification) [6]. These ASUs have reagent vials filled with solvents and precursor molecules 
connected to a reactor through various valves that can be programed to perform actions at a 
given time point. Today, there are commercially available kits that can be prepared and loaded 
on to ASUs to produce radiotracers routinely, examples of these include 18F-fluorodeoxyglucose 
([18F]FDG), 18F-fluorothymidine ([18F]FLT) and 18F-dihydroxyphenylalanine ([18F]DOPA). The 
synthesizer that was utilized to complete this work is the IBA Synthera®, which is a kit-based 
ASU allowing for automated processes including reformulation of the final tracer.   
The concept of molar activity (MA) needs to be taken into consideration when dealing 
with receptors that are saturable, present in low densities or if there as a competing ligand for the 
binding site. The MA of a radiotracer is defined as the radioactivity per unit mass of a labeled 
compound and is usually reported in Ci/µmole. The lower the density of the receptor, the higher 
MA is needed due to competition for the binding site between the labeled and unlabeled 
compounds [6]. Many factors can affect the MA of a radiotracer, including: tubing, reagents or 
gases that contain nonradioactive isotopes of the ones being used (eg. 19F in Teflon tubing) and 
any contamination that may be present in the cyclotron target. MA is not important when dealing 







1.5 Fluorine-18  
 
Fluorine-18 has many advantages over the other PET radioisotopes due to its ease of 
production in high quantities, longer half-life (109 mins), its positron decay (97%) and positron 
weak energy. Out of the available positron emitters for clinical use, 18F has the lowest mean 
positron emission energy of 0.64 meV and an average range of 0.83 mm in soft tissue (Table 
1.3) which has several important consequences. The dose of radiation received by the patient will 
be lower and the distance between disintegration of the radionuclide and the annihilation site 
(positron and electron) is reduced, which results in higher resolution PET images [7]. The 
challenge of working with F-18 is that it is not common in biological molecules.  [4]. Fluorine 
can act as a bioisostere for  hydrogen and oxygen as they have similar radii, and substituting a 
hydrogen/oxygen atom for a fluorine atom does not usually result in substantial steric differences 
between both molecules [7]. However, the electronegativity difference that comes with fluorine 
can change the physicochemical properties of the molecule (reactivity, hydrogen bonding, 
interaction with receptors, metabolism) which means that the biological activity of the 
fluorinated analog must be assessed.  
There are many constraints imposed on radiosyntheses such as: radiation protection, 
working in hot-cells with ASUs, fast reaction times and the need for obtaining the radiotracer 
with high MA, chemical purity and radiochemical purity. The total synthesis time including 
synthesis, final purification (usually through high pressure liquid chromatography (HPLC)), 
formulation and the quality control (QC) must be completed as quickly as possible with the 
incorporation of the radioactive isotope as late as possible in the reaction scheme [4]. It is 
important to note that high yielding reactions are not necessarily the goal of radiochemistry 






obtain an image. Rather, the purity and reliability of the radiotracer production is desired and 
optimized by the radiochemists. 
1.6 Radiolabeling with F-18  
 
In order to incorporate 18F into a molecule, this requires either electrophilic fluorination 
starting from molecular fluorine [18F]F2, or nucleophilic substitution starting from the fluoride 
ion [18F]F- [4]. These variants of 18F depend on the target material being bombarded in the 
cyclotron. When the target is 18O enriched water, an aqueous solution of [18F]F- is obtained and 
when the target is 18O2 gas, [18F]F2 gas is obtained. The advantage of working with nucleophilic 
[18F]F- is that the reaction is much more efficient giving higher amounts of radioactivity and MA 
than electrophilic 18F production [2]. In the case of [18F]F- production, the [18F]F- anion is 
obtained and trapped on an anion exchange cartridge, and then generally eluted with a solution 
containing: potassium carbonate dissolved in a minimum of water and cryptand (Kryptofix-222) 
mixed with acetonitrile (MeCN), which increases the nucleophilicity of the [18F]F- by 
complexing with the potassium cation eventually trapped within the cryptand. The water is then 
dried through azeotropic evaporation with MeCN allowing the[18F]F- to react with a precursor 
[4]. For [18F]F2, a carrier (19F-F2) gas is sometimes added to extract the [18F]F2 from the target 
which in turn reduces the MA and the theoretical radiochemical yield of electrophilic 
fluorination reactions. This has led to the majority of radiopharmaceuticals being prepared with 
nucleophilic [18F]F- methods [2].  
For nucleophilic fluorination, [18F]F- can be introduced into aliphatic positions through 
SN2 reactions or into aromatic molecules via nucleophilic aromatic substitutions (SNAr). 
Nucleophilic substitutions are carried out in polar aprotic solvents such as dimethyl sulfoxide 






100 – 150˚C. Nucleophilic substitutions require precursors with good leaving groups, with the 
reactivity of leaving groups as follows: Cl < Br < I < tosylate < mesylate < nosylate < triflate [2]. 
The better the leaving group, the less likely you are to form undesired by-products through 
competitive side reactions. Depending on the stability of the precursor and other functional 
groups on the molecule, it may be necessary to complete the fluorination in the first step 
followed by the removal of a protecting group or conversion of an intermediate into the final 
product in a second step [2]. Examples of radiopharmaceuticals prepared by SN2 reactions 
include: [18F]FDG, [18F]FLT, 18F-Fluoromisonidazole ([18F]FMISO) and 
[18F]Fluoroethylflumazenil (Figure 1.4). SNAr substitutions are more favorable for activated 
phenyl rings via the presence of electron withdrawing groups (eg. -CN, -CF3, carbonyl) located 
either ortho or para to the leaving group, although SNAr substitutions are still possible without 
activation through recently developed methods including boronic esters and iodonum ylides 
[17A,17B]. Activated phenyl groups limit the availability of molecules that can be labeled via 
SNAr substitutions, however, there are still several radiopharmaceuticals prepared by this 
technique, such as: 6-[18F]fluorodopamine, (-)6-[18F]fluoronorepinepherine, and [18F]Fluoro-
Setoperone (Figure 1.4) [2, 16].  
Recently, there has been an interest in labeling bioactive molecules such as peptides, 
proteins and oligonucleotides because of their specificity in vivo. The challenge in radiolabeling 
these molecules lies in the fact that they are not stable under radio-fluorination conditions and 
often do not have easily accessible labeling sites [17]. Therefore, two methods have been 
developed to meet the need for labeling bioactive molecules. The first method is direct labeling 
and it involves [18F]F- substitution directly on the biomolecule that may have undergone 






however, could suffer from poor MA due to difficulties in separating the modified precursor (eg 
Br- or Cl-analogs) from the desired 18F-labeled product [17]. Furthermore, the harsh reaction 
conditions, (pH, temperature) may cause hydrolysis of the biomolecule. The second approach for 
labeling biomolecules is the indirect method involving radiolabeling of a small prosthetic group 
as a first step, followed by attachment of the prosthetic group to the biomolecule via amine or 
thiol reactions, alkylation,  amidation, imidation or click chemistry [2]. Choosing a prosthetic 
group and the labeling site on the biomolecule is critical because this can affect the physical and 
physiological characteristics of the labeled molecule [18]. A typical 18F-labeled prosthetic group 
synthesis involves multiple steps with a purification step in between the conjugation with the 
biomolecule to remove fluorination reagents and other by-products that can be produced. The 
short half-life of 18F remains a challenge when designing an indirect radiosynthesis [2].   
1.7 Hexadecyl-4-[18F]fluorobenzoate  
 
Hexadecyl-4-[18F]fluorobenzoate ([18F]HFB)  is a long chain fluorinated PET tracer that 
was first developed by Ma et al in 2005 [19]. [18F]HFB was prepared in a one-step synthesis by 
SNAr  substitution of [18F]F- on hexadecyl-4-(N,N,N-trimethylamino)benzoate triflate (Figure 
1.5). Quaternary ammonium (Qat) analogs, with a triflate as a counter-ion, have been shown to 
be good leaving groups on aryl derivatives for SNAr fluorination, when combined with an 
electron withdrawing carbonyl at the para/ortho position (Figure 1.6). This results in electron 
density being pulled away from the Qat, making it susceptible to nucleophilic substitution by 
[18F]F-. [18F]HFB was employed to label rat mesenchymal stem cells (MSCs). Due to its high 
lipophilicity, [18F]HFB was efficiently and quickly absorbed into the cellular membranes of the 






labeled MSCs were then imaged in a rat via µPET imaging allowing for short term in vivo 
tracking of the biodistribution of the labeled stem cells [19].  
 [18F]HFB was then utilized by Zhang et al [20] to label human circulating progenitor 
cells (CPCs) to evaluate cell tracking in a rat myocardial infarction model and this was compared 
to CPC labeling with [18F]FDG. It was determined that [18F]HFB cell labeling efficiency and 
stability was superior to that of [18F]FDG, whereas neither labeling approach significantly altered 
cell viability, phenotype or migration potential up to 24 h post-labeling [20]. The [18F]HFB-CPC 
signal in the target area was greater than that of [18F]FDG-CPCs, however, only 16-37% of the 
initial injection dose was retained in the injection site at 10 min post-delivery. It was concluded 
that compared to [18F]FDG labeling, human CPCs labeled with [18F]HFB provided a more 
efficient, stable, and accurate method to quantify the distribution of transplanted cells and that 
PET imaging can be applied to enhance understanding of early retention, homing, and 
engraftment with cardiac cell therapy [20].  
 [18F]HFB proved to be a versatile radiotracer when it was implemented to label an 
injectable collagen based biomaterial to evaluate the retention and distribution after injection. 
[18F]HFB and Qdot labeling were used to evaluate collagen matrix delivery in a mouse model of 
myocardial infarction via PET or fluorescence imaging, respectively. [18F]HFB was non-
covalently linked to the collagen matrix and demonstrated an 82% labeling efficiency, compared 
to 96% for covalently bound Qdots [21]. The study conducted by Ahmadi et al concluded that 
[18F]HFB labeling along with PET imaging as a promising modality for assessing the 
biodistribution of injectable biomaterials for applications in the heart [21].  
 Taken together, the work using [18F]HFB proved that this radiotracer has the potential to 






we describe the automated kit-based synthesis of [18F]HFB using the Synthera® to produce large 
amounts of radioactivity in high concentrations that can be utilized for long term biodistribution 
studies.  Two of the studies cited looked at only the heart, however, [18F]HFB has many possible 
applications outside of cardiology, as we will see in the following chapter.  
Chapter 2: Applications of [18F]HFB 
2.1  Drug Delivery Nanovesicles 
 Many research efforts have been dedicated to developing alternatives to traditional drug 
delivery methods to increase the bioavailability, therapeutic index and enhance the activity of 
drugs as well as decrease the degradation of other biologically active drugs. To this end, 
nanoparticles have been employed as drug delivery vectors and have been loaded with small 
molecules, peptides, proteins, DNA or siRNA [22]. Due to their structure (1 to 100 nm), 
nanoparticles have many unique properties, such as being able to efficiently cross barriers such 
as the blood-brain barrier (BBB) [23] and can be transported transdermally [24]. Furthermore, 
nanoparticles go through a process known as passive targeting to get to their targets. To enter 
tissues, nanoparticles must circulate through the blood stream. Macrophages and neutrophils that 
line the liver and spleen engulf large sized particles (250 – 1000 nm), whereas small particles 
flow through endothelial gaps [22]. Therefore, nanoparticles need to be small enough to avoid 
being eliminated through phagocytosis, but must be above a certain size to prevent absorption in 
the blood. Through various experiments, it was concluded that particles approximately 20 – 100 
nm in diameter are the ideal size for efficient delivery to target tissues [25].  
2.2 Exosomes as natural nanoparticles 
 Exosomes are 30 – 150 nm membranous vesicles that are endogenously produced by 
most cell types. Exosomes were initially believed to be a means to dispose of cellular waste, 






impacts [3]. Exosomes contain the critical nanoparticle characteristics required for drug delivery 
and possess additional unique characteristics such as targeting specificity as well as their 
intrinsic biological effects on the targeted cells due to the exosome cellular origin [22].  
 Exosomes are believed to originate from endosomes (or multivesicular bodies (MVBs) as 
intraluminal vesicles (ILVs). Early endosomes mature into late endosomes and during this 
process, they accumulate ILVs in their lumen. The ILVs that are formed by inward budding of 
the early endosomal membrane sequester proteins, lipids, and cytosol that are specifically sorted 
[3]. Once the ILVs are formed, the MVB can fuse to a lysosome and be degraded by lysosomal 
hydrolases or fuse to the plasma membrane and release the newly formed exosomes [26] (Figure 
2.1). To fuse to the plasma membrane, exosomes have been shown to require specific Rab 
proteins for docking and fusing of the MVB to the plasma membrane, although this is dependent 
on the cell type [27].  
Due to their unique biogenesis mechanism, exosomes have plasma membrane-derived 
receptors on their surface and cytoplasmic contents inside. The lipid composition of the exosome 
lipid bilayer includes cholesterols, ceramides, lipid rafts, and sphingomyelin, and surface protein 
markers such as Alix, TSF101, CD63, CD9, CD81 and HSP70 [26]. Exosomes can be isolated 
from a variety of fluids and tissues, including but not limited to:  blood, urine, breast milk, liver 
cells, bone cells, and saliva. The content of exosomes varies based on the cell type they are 
obtained from, although in general, exosomes contain DNA, miRNA, cytoskeletal and heatshock 
proteins, MHC class I and II molecules, and peptides [28] 
2.3 Exosomes and drug delivery  
 
Recent research demonstrates that exosomes play a critical role in intracellular 






miRNAs, peptides and proteins [26]. It was shown that exosomes promote tumor invasion and 
exosomes derived from tumor cells can transfer their contents to distant sites in mice and induce 
tumors. It was suggested that preventing the production of tumor-derived exosomes could block 
tumor invasion and this was accomplished through studies using knockdowns of Rab27a, which 
led to a decrease in primary tumor growth [29]. Furthermore, it was demonstrated that exosomes 
could reach the central nervous system via intranasal administration of exosomes leading to the 
efficient delivery of curcumin and an anti-Stat3 inhibitor to the brain [30]. Exosomes are not 
cytotoxic in the brain, and are more efficient than synthetic nanoparticles in the delivery of 
agents to the brain, making them a delivery vehicle of choice [22]. Exosomes were also recently 
tested as drug delivery vehicles for Parkinson’s disease (PD) therapy by a group at the University 
of North Carolina. Exosomes were loaded ex vivo with a potent antioxidant (catalase) used to 
treat PD and these were evaluated in a mouse model of PD. The catalase loaded exosomes 
provided significant neuroprotective effects in vitro and in vivo models and provided evidence 
that exosomes can represent a strategy to treat inflammatory and neurodegenerative disorders 
[31]. Therefore, there is increasing evidence of the benefit of gaining a better understanding of 
exosomes for their roles in clinical therapeutics.  
2.4 SiRNA as a drug  
 
The 2006 Nobel Prize in medicine was awarded for the discovery of a new type of drug: 
small interfering RNA (siRNA). siRNAs 20-25 base pairs of double stranded RNA molecules 
that can specifically silence any gene. siRNAs are incorporated into the RNA interfering-induced 
silencing complex (RISC), which mediates mRNA sequence specific binding and cleavage [32]. 
In other words, siRNA interferes with the expression of specific genes with a complementary 







siRNA has the potential to treat virtually any disease, however, there are many current 
limitations to using siRNA therapeutically. The major extracellular limitations to siRNA delivery 
include: siRNA degradation, aggregation of siRNA nanoparticles in serum, and targeting [32]. In 
the body, siRNAs are easily degraded by RNAses and free siRNAs have a half-life of only 
several minutes to an hour [33]. Chemical modifications can be made to the siRNA structure to 
stabilize the siRNA in serum, however, this does not solve the problem of targeting. 
Nanoparticles have been developed using monoclonal antibodies or ligands to specifically target 
antigens or cell surface receptors [32]. Successful results were obtained including a monoclonal 
antibody-protamine fusion protein to selectively target leukocytes containing lymphocyte 
function associated antigen-1 integrins [34] and N-acetylgalactosamine modified nanoparticles to 
target hepatocytes [35]. The internalization of the nanoparticles inside the cells was observed to 
be a problem as well as the aggregation of the nanoparticles due to the surface charge of siRNA 
loaded nanoparticles (net positive) [32]. In the human body, siRNAs are produced and 
transported using exosomes. This provides both protection and specific targeting for the siRNA. 
Utilizing exosomes for the delivery of specific siRNA sequences could unlock a whole new 
therapeutic approach to treating many diseases. This approach was recently applied to deliver 
siRNA loaded, lamp2b modified exosomes to a mouse brain via systemic injection. The siRNA 
resulted in the knockdown of BACE1, a therapeutic target in Alzheimer’s disease, without non-
specific uptake in other tissues [36].  
Taken together, these studies demonstrate that exosomes are excellent candidates for the 
targeted delivery of small molecules, proteins, peptides, miRNAs, siRNAs and other important 
molecules that would normally be degraded by the cell [26]. This would help overcome the 






treatment of many diseases. To accomplish this, more work is needed in understanding how 
exosomes function and traffic in vivo.  
2.5 Challenges with Exosomes and drug delivery  
 
 The unique biogenesis of exosomes produces exosomes with receptors on their surface 
that cause them to interact with specific cells in a highly selective fashion. To utilize the cell to 
cell communication system that exosomes possess for the therapeutic application of exosomes as 
drug delivery vehicles, it is necessary to gain a better understanding of where exosomes traffic in 
the body. Many technical challenges have led to difficulties in studying exosome trafficking and 
no robust studies of exosome trafficking have been published. Exosomes are extremely small and 
therefore difficult to strongly label without altering their biological functions. An imaging probe 
must be introduced in a way that maintains the physiological and structural integrity of the 
system/cell in question [37]. Furthermore, it is very expensive and demanding to produce 
exosomes, with typical studies to inject a single mouse requiring purifying exosomes from 200 
mL – 1 L of cell culture [3]. Current approaches to follow exosome trafficking in vivo have used 
fluorescent hydrophobic dyes (DiR). These dyes require large amounts of exosomes for 
trafficking studies and they have also been shown to form micelles that co-purify with exosomes 
or surround exosomes. This results in inconclusive results related to the trafficking of exosomes. 
Therefore, there is an urgent need for a highly sensitive technique to follow exosome trafficking 
in animals. PET imaging of exosomes could solve the key issue in the studies of exosome 
physiology and allow for a comprehensive study of their trafficking in vivo.  
2.6 Radiolabeling Exosomes 
		
 As previously mentioned, PET has been implemented during the drug development 






date, the only paper published on radiolabeled exosomes to study their trafficking was completed 
by a group in South Korea [5]. The approach utilized exosome-mimetic nanovesicles derived 
from macrophages labeled with 99mTc-hexamethylpropyleneamineoxime (HMPAO) combined 
with SPECT/CT to monitor the in vivo distribution of the exosomes in mice. 99mTc-HMPAO is 
an uncharged, highly lipophilic radiotracer that has been utilized for cell labeling. Intracellular 
glutathione converts 99mTc-HMPAO to its hydrophilic form, trapping it inside the cell [5]. The 
exosome-mimetic nanovesicles were incubated with 99mTc-HMPAO for 1 hour, followed by a 
purification to remove free 99mTc-HMPAO and analysis via instant layer thin chromatography 
(ITLC). The expression of the exosome specific protein CD63 did not change after radiolabeling 
and the labeled vesicles showed high serum stability (90%). The SPECT/CT images of the mice 
injected with 99mTc-HMPAO exhibited high uptake in the liver and no retention in the brain, 
whereas mice injected with 99mTc-HMPAO only displayed high brain uptake (Figure 2.2) [5].  
 Taking this approach one step further with PET imaging would allow for an even more 
robust study of exosome trafficking. Exosomes have never been labeled with an 18F-based 
radiotracer and [18F]HFB has potential for success. [18F]HFB is highly lipophilic and resembles 
the lipids found in the bi-layer of the exosome membrane. Based on previous studies using 
[18F]HFB to label cells, it is quickly absorbed within cell membranes and it should not disrupt 
the cell function. SPECT provides lower-resolution images that are prone to artifacts and 
attenuation, as compared to PET images. Furthermore, in the study using 99mTc-HMPAO, 
exosome-mimetic vesicles were used due to ease of purification and the larger mass of mimetic 
vesicles obtained as compared to true exosomes. The trafficking of exosomes obtained from 






from different cell types traffic to in the body will be key in the therapeutic application of 
exosomes as drug delivery vehicles.  
2.7 Injectable Biomaterials 
		
 Another promising application of radiotracers is for radiolabeling injectable biomaterials. 
With the increasing use of cells and injectable biomaterials for the treatment of disease and 
regeneration of tissues, there is a clear need for imaging methods that allow to follow their 
injection and possible migration within the body. Hydrogels are highly biocompatible, three-
dimensional hydrophilic polymer networks, capable of absorbing large amounts of water or 
biological fluids [38]. Their high-water content and soft consistency makes hydrogels similar to 
natural tissues. Hydrogels can be made from various materials including protein-based polymers 
(collagen, fibrin and gelatin), carbohydrate-based polymers (cellulose derivatives, agarose, 
alginate, hyaluronate and chitosan) and fully synthetic polymers (polylactic acid and 
polyglycolic acid) [38]. Recently, Dr. Sophie Lerouge’s group at the CRCHUM has developed 
chitosan-based thermosensitive hydrogels for the treatment of disease and regeneration of 
tissues. Chitosan is a natural hetero-polymer chain with ß(1-4) linked D-glucosamine and N-
acetyl-D-glucosamine residues, obtained by alkaline deacetylation of chitin, one of the most 
abundant polysaccharides obtained from crustaceans [39] (Figure 2.3). The chitosan hydrogels 
are obtained by mixing an acidic solution of chitosan with a mixture of weak bases, namely 
sodium hydrogen carbonate (SHC) with phosphate buffer (PB) or beta-glycerophosphate (BGP) 
as gelling agents (GA). These hydrogels are thermosensitive and quickly gel in vivo in a non-
reversible manner. Their iso-osmolality, physiological pH and macroporisity are suitable for cell 






such as blood vessel embolization, drug delivery, lymphocyte delivery systems and cartilage and 
intervertebral disc repair [38-40].  
When working with biomaterials, an important factor to consider is the mechanical properties 
of the hydrogels as well as the gelation kinetics (rheological properties). The secant modulus of 
elasticity refers to the ratio of stress to strain at any point on the curve of a stress-strain diagram 
(the slope of a line from the origin to any point on a stress-strain curve) whereas the storage 
modulus is an indicator of the ability to store deformation energy in an elastic manner [39]. 
Furthermore, the gelation kinetics refers to the time it takes for the hydrogel to fully gel and can 
change depending on the formulation of the hydrogel. These properties are unique to a given 
biomaterial and must be considered/measured when making changes to the formulation of a 
biomaterial as we will see when radiolabeling hydrogels.   
2.8 Radiolabeling Hydrogels 
		
 The safety and efficacy of minimally invasive procedures, (hydrogels), is determined by 
the behavior of the injectable scaffolds and cells in vivo. Therefore, there is an urgent need for in 
vivo, short term follow up of such procedures to assess the retention of the hydrogel and cells at 
the site of injection. The high sensitivity of PET, combined with its non-invasive imaging 
capabilities make it an ideal candidate for the study of hydrogels. Vascular endothelial growth 
factor (VEGF) loaded chitosan hydrogels were previously labeled by Kim et al using I-131 and 
analyzed via autoradiography in rat myocardial infarct models [41]. I-131 is better suited for 
long term studies due to its long half-life of 8 days, however for short term distribution studies, 
18F is the radioisotope of choice for PET studies. [18F]HFB was previously employed by Ahmadi 
et al for the non-covalent labeling of a collagen based biomaterial. The group saw high retention 






here to assess the in vivo distribution of chitosan-based hydrogels. Chitosan hydrogels have 
never been labeled with an 18F-based radiotracer for PET imaging. Radiolabeling of chitosan 
hydrogels with [18F]HFB would allow to determine their retention and possible migration at the 
site of administration in vivo in small animals. Understanding the biological mechanisms and 
local effects of transplanted cells remains mostly restricted to postmortem histological 
assessment, whereas PET provides an effective alternative to this.  This method will allow for 
the determination of the localization in vivo and efficacy of injectable hydrogels that have the 






















Table 1.1. Common imaging modalities and their characteristics (Adapted from: [9]). 
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Figure 1.1. The PET concept. A radiolabeled tracer is injected into a patient, a positron is 
emitted from the tracer through beta decay. The positron produces an annihilation event with an 
electron resulting in the production of two 511 keV photons at ~ 180˚ which are detected by the 









Table 1.2. Physical characteristics of the most commonly utilized positron emitters for 
clinical use.  
Isotope T1/2 (min) % (Beta decay) Common nuclear 



















Figure 1.2. Decay scheme for fluorine-18. Unstable, high-energy fluorine 18 decays, primarily 


























Figure 1.3. PET coincidence detection along the LOR. The circular arrangement of block 













Figure 1.4.  Various [18F] radiosynthetic reactions. [18F] drying after cyclotron production 
and nucleophilic aliphatic and aromatic [18F] substitution reactions. Figure adapted from [2].  
Figure 1.5. Synthesis of Hexadecyl-4-[18F]fluorobenzoate ([18F]HFB) from the 













Figure 1.6. Reaction mechanism and resonance through activation of the phenyl 
ring by the carbonyl group on the precursor: hexadecyl-4-(N,N,N-

























Figure 2.1. The biogenesis of exosomes. Once the MVB is formed, it can fuse to a lysosome 
and be degraded or fuse to the plasma membrane to release the newly formed exosomes (as 













Figure 2.2. SPECT/CT images of mice injected with 99mTc-HMPAO labeled exosome- 
mimetic vesicles and free 99mTc-HMPAO. After 5h, the labeled exosome-mimetic vesicles 
showed higher uptake in the liver, whereas the free 99mTc-HMPAO sowed higher brain 
uptake. Figure adapted from [5].   







Thesis Overview  
2.1 Hypothesis 
	
The radiosynthesis of [18F]HFB can be automated in high purity to label exosomes and 
chitosan-based hydrogels for in vivo distribution studies using PET imaging.  
2.2 Objectives  
 
1. The [18F]HFB precursor (hexadecyl-4-(N,N,N-trimethylamino)benzoate triflate) and non-
radioactive HFB will be produced as standards.  
2. Synthesize [18F]HFB in high chemical and radiochemical purity (>95%), in a reproducible 
manner using the cassette-based Synthera® ASU module.  
3. Produce [18F]HFB with a final formulation that will have the appropriate solvent 
composition and pH for working with exosomes and living cells. 
4. Use [18F]HFB to radiolabel exosomes and chitosan-based hydrogels.  
4.1 The radiolabeling of exosomes should not alter their structure and/or trafficking in 
vivo.  
4.2 The radiolabeling of the hydrogels should not have any adverse effects on their 


















Materials and Methods 
3.1 Chemistry 
3.1.1 Materials  
 
All reagents and solvents were purchased from Sigma-Aldrich, classified as 98% purity 
(or greater) or HPLC grade, and used without further purification or manipulation. All 
reactions were performed in oven-dried glass round-bottom flasks equipped with magnetic 
stir bars. Analytical thin layer chromatography (TLC) was performed on silica gel 60 F254 
plates from EMD. Purification of reaction products was carried out by flash column 
chromatography using silica gel. A Phenomenex Luna C18(2) column (250 x 4.6 mm, 10 
µm) or a Shimadzu C18 (50x4.6 mm, 5 µm) were used for all analytical HPLC in 
combination with either a Shimadzu LC-20AB/SPD-20A HPLC system or a Waters 1525/ 
2489 HPLC system.  
1H-Nuclear magnetic resonance (NMR) was performed at the Université de Québec à 
Montréal department of chemistry using a Bruker 300 MHz at ambient temperature. Proton 
chemical shifts are reported in parts per million (ppm) using residual solvent as the internal 
standard (CDCL3 at 7.26 ppm), coupling constants (J) are reported in Hertz (Hz). Multiplicity 
is defined by s (singlet), br (broad), d (doublet), t (triplet), q (quartet), qn (quintet), sx 
(sextet), or m (multiplet). High-resolution mass spectrometry (MS) was performed by 
technicians at the CRCHUM in positive or negative ion mode using a Thermo Scientific Q-
Exactive Plus Orbitrap Mass Spectrometer via direct injection with no chromatograph. 








3.1.2 Experimental  
 
All compounds were prepared as per the literature [19] (Figure 3.1 and Figure 3.2).  
Synthesis of N-hexadecyl-4-(N,N-dimethylamino)benzoate 
 
Hexadecyl-4-(N,N-dimethylamino) benzoate was synthesized from 4-(N,N-
dimethylamino)benzoyl chloride (0.500 g, 2.72 mmol) and 1-hexadecanol (0.792 g, 3.26 
mmol) in the presence of triethylamine (0.76 ml, 5.4 mmol) and dichloromethane (DCM) (10 
mL). The reaction mixture was stirred at room temperature for 4 h and monitored via TLC. 
Once no starting material remained, the reaction mixture was extracted with water and DCM. 
The organic phase was dried over magnesium sulfate, filtered, concentrated and purified by 
column chromatography (9/1 dichloromethane/methanol (MeOH)). The product was 
recrystallized using a minimum of hot ethyl acetate to give pure N-hexadecyl-4-(N,N-
dimethylamino)benzoate.  
 
Synthesis of hexadecyl-4-(N,N,N-trimethylamino)benzoate triflate (Triflate Precursor) 
 
A mixture of N-hexadecyl-4-(N,N-dimethylamino)benzoate (0.2 g, 0.51 mmol) and 
methyl triflate (0.10 g, 0.61 mmol) in DCM (3 mL) was stirred overnight at room 
temperature under argon. The reaction mixture was monitored via TLC until no more starting 
material remained. The solvent was evaporated and the product was crystallized using 
hexanes/DCM. Analytical HPLC analysis was completed on the precursor (Shimadzu C18 









Synthesis of hexadecyl-4-fluorobenzoate (HFB Standard).  
1-Hexadecanol (0.183 g, 0.75 mmol) was dissolved in DCM (3 mL) and to this was 
added 0.175 mL (1.2 mmol) of triethylamine and 4-fluorobenzoyl chloride (0.1 g, 0.63 
mmol). The reaction mixture was stirred at room temperature for 3 h and the progress of the 
reaction was monitored via TLC. Once no starting material remained, the reaction mixture 
was extracted with water and DCM. The organic phase was dried over magnesium sulfate, 
filtered, concentrated and purified by column chromatography (96/4 hexanes/ethyl acetate). 
Analytical HPLC analysis was completed on the HFB standard. (Shimadzu C18 (50x4.6 mm, 
5 µm), 95/5 (MeCN/AF (0.1M), 1.5 mL/min). 




[18F]Fluoride was produced in our IBA Cyclone® 18 MeV cyclotron from proton 
irradiation of 97% [18O]H2O-enriched water via the 18O(p,n)18F nuclear reaction. Target 
water was delivered through polyethylene tubing and collected in a 10-mL vial in the 
dispensing cell. The radioactivity was transferred to the Synthera® once ready.  
The Synthera® ASU was purchased from IBA® (Figure 3.3), including two synthesis 
modules and one HPLC purification module (UV detector, radiation detector and HPLC 
pump). An automated syringe driver system was installed between the synthesis modules and 
the HPLC module. This was done to minimize the loss of product when transferring from the 
reactor in the synthesis module to the HPLC loop, as the previous system pushed the product 
directly to the HPLC loop using air. This can often result in losses through overshooting the 
HPLC loop, therefore, the HPLC loading was accomplished via a syringe driver system 






were purchased from ABX and used for a maximum of 5 runs each (cleaned in between each 
run). The IFP’s were slightly modified to accommodate larger reagent vials; positions 3 and 
4 on the IFP (Figure 3.5) were connected to external 30 mL and 10 mL vials, respectively. 
Phenomenex Luna C8(2) and C18 (2) columns (250 x 10 mm, 10 µm) were used for semi-
preparative HPLC with a mobile phase consisting of 95/5 MeCN/ammonium formate (AF) 
(0.1 M in water). The buffer was filtered through a 0.2 µm filter paper prior to use.  
Sep-Pak Light Waters Accell Plus QMA cartridges (Waters) were utilized to trap F-18 
from the target water. These QMA cartridges were conditioned by passing 5 mL of an 8.4% 
sodium bicarbonate solution, followed by 10 mL of water and drying. The C18 light (Waters) 
cartridges were conditioned by passing 5 mL of ethanol (EtOH) or MeOH followed by 10 
mL of water.  F-18 eluent was ordered from ABX and contained per vial:  22.6 mg 
Kryptofix2.2.2, 4.2 mg potassium carbonate, 0.3 mL anhydrous acetonitrile and 0.3 mL 
water for injection. A heating block set at 120˚C was implemented post purification to 
evaporate the HPLC solvent. The final product was reformulated using sterile DMSO and/or 
saline/1x phosphate buffered saline (PBS).  
3.2.2 [18F]HFB  
3.2.2.1 Experimental 
		
For every [18F]HFB run, either a new R&D IFP was used or a previously used IFP was 
cleaned and dried using a pre-programmed cleaning recipe with the reagent vials containing 
acetonitrile, EtOH and water (1 mL each). A minimum of 12 hours was given before opening 
the hot cell to allow for decay. Several different reaction conditions (fluorination 
temperatures of 80˚C, 100˚C and 140˚C and times 20 min and 30 min) were tested to 






maximizing yield of [18F]HFB. [18F]HFB was prepared via nucleophilic displacement of a 
Qat leaving group by [18F]fluoride ion (Figure 1.5).  
To remove any unreacted [18F]fluoride, other salts and dimethyl sulfoxide (DMSO) prior 
to going to semi-prep HPLC purification (to prevent damage to the column), the reaction 
mixture was passed through an activated C18 Seppak light cartridge. The elution conditions 
of HFB from a C18 light cartridge were tested by dissolving 0.5 mg of cold HFB in 600 µL 
of DMSO and passing this through a conditioned C18 light cartridge. The cartridge was then 
rinsed with 20 mL of water to remove the DMSO, and either MeCN or EtOH to elute HFB in 
0.5 mL fractions. These fractions were then analyzed via analytical HPLC to determine how 
much solvent was needed to completely remove HFB from the C18 light cartridge.  
A checklist was developed for the radiosynthesis of [18F]HFB in order to minimize 
human error prior to the synthesis. The first step in the radiosynthesis of [18F]HFB was to 
ensure that the HPLC solvent bottles (A and B) were full of solvent (1 L). Solvent bottle A 
contained 95/5 (MeCN/0.1M ammonium formate) and bottle B used for cleaning contained 
70/30 (MeCN/H2O). The HPLC procedure was then started which involved a loop and 
column cleaning with solvent B, followed by a column conditioning with solvent A. While 
this was running, slight modifications were made to the IFP to connect larger vials to 
positions 3 and 4 (Figure 3.5). This involved removing the tubing from the normal inlet to 
the reagent vials and connecting these to external 30 mL and 10 mL vials, respectively. The 
kit was then placed onto the synthera A module and the reagents were prepared as follows: 
vial 1:  Cryptand solution, vial 2: hexadecyl-4-(N,N,N-trimethylamino)benzoate triflate 






mL). Furthermore, the QMA light cartridge and C18 light cartridges were conditioned and 
placed in Sep-Pak positions 1 and 2 on the IFP (Figure 3.5).  
Before transferring [18F]F- to the synthera, the pre-synthesis HPLC conditioning and IFP 
tests were completed. The IFP tests involved pressurizing the reactor and reagent vials along 
with pushing air and turning the valves to ensure no lines were leaking, obstructed or vials 
malfunctioning. Once all the tests were passed, [18F]F- was transferred from the dispening hot 
cell to the synthera via the vaccum pump on the synthera module.  
3.2.2.2 Radiosynthesis 
[18F]F- (1 – 1.2 Ci) was trapped on a Waters Sep-Pak QMA light catridge through 
vaccum suction into the synthera module while the O-18 water was collected in a designated 
vial.  The [18F]F was eluted into the reactor using 0.6 mL of cryptand solution. The eluate 
was azeotropically evaporated at 110˚C for 5 min under nitrogen gas flow, leaving potassium 
[18F]fluoride complexed with Kryptofix 2.2.2. in the reactor. Next, 3 mg of  precursor in 600 
µl of DMSO was added to the reactor and fluorination was completed at 100˚C for 20 mins. 
Five mL of water was added to cool and dilute the reaction mixture, and this was passed 
through a C18 light cartridge, trapping [18F]HFB and organic compounds, and disposing of 
unreacted [18F]F- and salts. The cartridge was rinsed 3 times with 5 mL of water and then 
eluted using 4 mL of MeCN into an intermediate vial. An automated syringe driver system 
was used to transfer the eluate to semi-preparative HPLC purification using a C18 column. 
MeCN/0.1 M AF 95/5 at a flow of 10 mL/min was used as the mobile phase. The radioactive 
product peak (retention time ~ 20 min) was collected and transferred to the dispensing hot 
cell. The HPLC solvent was evaporated at 120˚C under nitrogen flow and vacuum aspiration. 






final concentration/activity. The formulation was filtered through a 0.22 µm filter (DMSO 
resistant Acrodisc®) into 4.5 - 6.3 mL of sterile saline or PBS for a final tracer formulation 
of 10% DMSO/Saline. The total synthesis time including purification was approximately 60 
mins.  
3.2.3 Quality Control  
 
Post-synthesis quality control (QC) was completed using analytical HPLC to confirm the 
product identity, purity and calculate the molar activity of [18F]HFB. Analytical HPLC was 
completed using a Phenomenex Luna C18(2) column (250 x 4.6 mm, 10 µm) and a mobile 
phase of 99/1 (MeCN/AF (0.1M)).  An aliquot of the final formulation of [18F]HFB was co-
injected with cold standard to confirm the product identity. Molar activity was calculated by 
injecting [18F]HFB alone and comparing the area of the UV absorbance peak (254 nm) to that 
of a known amount of standard. Gas chromatography was completed with an Agilent 7890B 
GC system with a 7697A Headspace sampler. Instant TLC (ITLC) was analyzed using an 
Eckert & Ziegler TLC scanner (B-AR200-1). All radioactivity was measured using a 
Capintec CRC-55tW.  
3.2.3.1 Gas Chromatography Analysis 
 
Gas chromatography (GC) analysis was completed to measure the amount of residual 
solvent that remained in the final formulation, after evaporation. Two approaches were tested 
to ensure full evaporation of the HPLC solvent. The first approach involved placing 15 mL of 
HPLC solvent (95/5 MeCN/AF (0.1M) in a 30-mL product vial, evaporating at 120˚C until 
no solvent remained and then adding an additional 2 minutes to ensure dryness. The second 






dryness. 5 mL of saline was then added to the vials and GC analysis was completed to test 
for residual: methanol, ethanol, acetone and acetonitrile.  
3.2.3.2 Calculating Molar Activity  
 
A specific volume of standard of known concentration was injected onto analytical HPLC 
and the area under the curve (AUC) was recorded (254 nm). A sample of the final 
formulation of [18F]HFB was then injected in a separate injection and the activity in the 
syringe was measured before and after injection. The AUC of the injected [18F]HFB was 
recorded (254 nm) and the amount of cold mass in the product was determined by comparing 
the two AUCs with respect to the amount of standard injected.  
3.3 Labeling exosomes and hydrogels with [18F]HFB  
 
3.3.1 Materials  
 
Exosome exclusive spin columns (MW 3000) and instant thin layer chromatography 
(ITLC) paper was ordered from Thermo Fisher scientific and disposable PD10 (MW 5000) 
desalting columns were ordered from sigma Aldrich. Purified exosomes obtained from 
different sources (lung, liver, bone) were provided by Dr. Derrick Gibbing’s lab at the 
University of Ottawa Faculty of Medicine. Centrifugation for exosome purification was 
completed using a TL-100 Ultracentrifuge (TLA 100.3 rotor). Following radiolabeling, 
removal of [18F]HFB from labeled exosomes was completed using one of two centrifuges: a 
Thermoscientific Legend Micro21R or a Beckman Coulter Optima L-90K ultracentrifuge 
with a SW40TI rotor.  
Chitosan (Chitoscience 95/100, DDA 92.6%) was purchased from Heppe Medical 
Chitosan (Germany), ß-glycerophosphate disodium salt pentahydrate (BGP) 






hydrogen carbonate (NaHCO3, hereafter SHC) was purchased from MP Biomedicals (Solon, 
OH, USA) and provided by Dr Sophie Lerouge’s lab at the CRCHUM and used without 
further manipulation.  
3.3.2 Experimental  
 
3.3.2.1 Exosome Purification  
 
Exosomes were purified and isolated by sequential centrifugation by members of the 
Gibbings lab. All the centrifuge tubes were balanced using PBS. Briefly, the supernatant 
media fluid from a cell culture dish was transferred into a 50-mL centrifuge tube and 
centrifuged at 300 x g at 4˚C for 10 min. The supernatant was then transferred into a new 50 
mL centrifuge tube and centrifuged at 2000 x g at 4˚C for 10 min. The supernatant was then 
transferred into an ultracentrifuge tube and centrifuged at 10,000 x g at 4˚C for 30 minutes. 
The supernatant was then transferred to a new ultracentrifuge tube and centrifuged at 100,000 
x g at 4˚C for 2 hours. The supernatant was then removed and the pellet resuspended in 1 mL 
PBS. The pellet solution was transferred to a 1.5 mL ultracentrifuge tube and centrifuged at 
100,000 x g at 4˚C for 15 mins. The supernatant was removed and the exosome pellet was 
resuspended in a small volume of PBS (20-34 µL). The exosomes were then stored at 4˚C 
and shipped to the CRCHUM until used.  
3.3.2.2 Exosome Radiolabeling using [18F]HFB 
 
3.3.2.2.1 Exosome labeling conditions  
 
Several strategies were implemented to label exosomes, based on the radiolabeling of 
exosome-mimetic vesicles using 99mTc-HMPAO and labeling of exosomes using fluorescent 
dyes (unpublished work complete by the Gibbing’s lab) (Figures 3.6 and 3.7). The final 






desired concentration/activity per incubation with exosomes.  Three different incubation 
temperatures were tested: 4˚C, room temperature (RT) and 37˚C with an incubation time of 
30 min. Each Eppendorf tube of purified exosomes obtained from the Gibbing’s lab 
contained approximately 16 µg of exosomes dissolved in ~ 34 µL of PBS. An Eppendorf 
tube was either used completely or split into various aliquots.  The incubation volumes, 
temperatures and times that were investigated along with centrifugation conditions are 
indicated in Table 3.1. For each labeling condition, a control was also completed without 
exosomes where the volume of the exosomes was replaced with PBS.  





















5 495 -- 500 4, RT, 37/30 12,000 rpm/1hr PBS/DMSO 
8 400 -- 408 37/30 200,000 x g /1h, 
2h, 4h,  
--------- 
10 990 -- 1000 4, RT, 37/30 21,000 rpm/1 hr PBS 
34 200 -- 234 37/30 21,000 rpm/2 hr PBS/DMSO 
34 50 -- 84 37/30 200,000 x g/ 4h --------- 
34 50 50 134 37/30 200,000 xg/4h  --------- 
 
The effect of bovine serum albumin (BSA) on the radiolabeling of exosomes was also 
investigated through completing a 30 min incubation of BSA at 37˚C with [18F]HFB prior to 
the addition of exosomes. Furthermore, normal Eppendorf tubes and low retention Eppendorf 






3.3.2.2.2 Purification strategies  
 
Various strategies were tested to remove free [18F]HFB from labeled exosomes 
including exosome exclusive spin columns, PD10 size exclusion desalting columns and 
centrifugation. For the exosome exclusive spin columns, the columns were hydrated with 650 
µL of 1x PBS for 15 min at RT. The spin column was then placed in a 2-mL collection tube 
and spun at 750 x g for 2 min at RT to remove excess interstitial fluid. The collection tube 
was discarded and the sample (maximum volume of 100 µL/column) was loaded directly 
onto the center of the gel bed. The column was then placed in a 1.5 mL elution tube and spun 
at 750 x g or 500 x g for 1 – 2 min at RT. The elution tube was collected and analyzed. A 
gravity protocol was used for the PD10 desalting columns, where the column was first 
equilibrated with 25 mL of 1x PBS or 25 mL of 1x PBS + 0.1% Tween, followed by sample 
application ([18F]HFB reformulated in 10% DMSO/PBS, 5% DMSO/PBS or 
10%DMSO/PBS + 0.1% Tween)  and elution using 1x PBS or 1x PBS + 0.1% Tween. 
Fractions (0.5 mL) were collected. The force of centrifugation varied from 12,000 rpm – 
21,000 rpm to 200,000 x g in the ultracentrifuge. Centrifugation times also varied from 1 to 4 
hours, with a washing step completed using PBS or 10% DMSO/PBS (in select experiments). 
Due to the long-time constraints of the ultracentrifugation (up to four hours), and the loss of 
activity associated to this step, the washing step following ultracentrifugation was by-passed. 
After centrifugation, the supernatant was collected and the pellet resuspended in a small 
volume of PBS (60 - 200 µL) PBS. Both the supernatant and resuspended pellet were 
analyzed via ITLC to confirm labeling. ITLC was also completed on the samples prior to 






analysis was completed with a mobile phase of 9/1 (MeCN/AF (0.1M). Furthermore, the 
radioactivity in the tubes after each step or transfer was measured.  
3.3.2.3 Hydrogel Preparation  
 
 Raw chitosan (CH) was first purified by dissolution in 0.1M hydrochloric acid and 
stirring overnight at 40˚C. The solution was then filtered under vacuum and the CH was 
precipitated with 0.5 M NaOH under continuous stirring. Sodium dodecyl sulfate (SDS) 10% 
(w/v) was added to the slurry and heated at 95˚C for 5 min. After cooling down to room 
temperature, the pH was adjusted to 10 with 0.5 m NaOH. The slurry was filtered under 
vacuum and hydrated CH was washed with Milli-Q water at 40˚C. The CH was then freeze-
dried, ground and sieved to obtain a dried and purified CH powder.[39].  
A CH solution of 3.33% (w/v) was prepared by dissolving purified CH powder in 
0.12 M hydrochloric acid at room temperature, and the solution was sterilized by autoclave at 
121˚C for 20 min and stored at 4˚C. Each hydrogel was prepared at room temperature by 
mixing sterilized CH solution with a gelling agent (GA) solution (containing BGP and SHC 
to get final concentration of 0.1 M and 0.075 M in the gel, respectively) by using two 
syringes and a female-to-female Luer-lock syringe connector. This was previously shown to 
form a hydrogel which remains liquid at room temperature but rapidly gels at body 
temperature.  
3.3.3.3 Effect of DMSO on Chitosan Hydrogels  
 
Since the final formulation of [18F]HFB contains 10% v/v DMSO in saline, primary 
tests consisted in testing the possible negative effect of DMSO on the gelation kinetics and 
mechanical properties of the chitosan hydrogels. 10% DMSO/saline solution mixed with the 






DMSO/saline solution was mixed to the acidic chitosan solution prior to adding GA 
(Approach 2: (CH+ DMSO + GA). The volume and initial concentration of GA was adjusted 
each time.  
Both mixing approaches described above were tested, using 10% DMSO in water 
(without HFB). Different volumes of DMSO/saline solution were tested: 0.2 mL, 0.1 mL and 
0.05 mL (2%, 1% and 0.5% v/v, respectively), while the volume and initial concentration of 
GA solution was varied (0.2 mL, 0.3 mL and 0.35 mL of the GA at concentrations of 2x, 
1.33x and 1.14x, respectively) to keep the final concentration of each compounds constant 
within the 1mL gel solution. The rheological properties of the hydrogels during gelation at 
37°C were compared, as well as their mechanical properties in compression after 24h 
gelation.  
Rheological properties were investigated using an Anton Paar instrument (Physica MCR 
301, Germany) with a coaxial cylinder geometry (CC10/T200) in the linear viscoelastic 
region (at 5% strain and 1Hz frequency). The evolution of the storage (G’) and loss (G”) 
moduli was measured during 1h at 37 °C, immediately after mixing the hydrogel 
components.  
After complete gelation, unconfined compression tests were performed using a Bose 
ElectroForce 3200 instrument equipped with a 200 N load cell. Hydrogel solution (2mL) was 
added into cylindrical molds (14 mm diameter) and incubated at 37 °C for 24 h. Samples 
were gently removed from the container and a compression was applied at a constant rate of 
0.5 mm s−1 until reaching 50% deformation. The secant Young’s moduli were calculated as 






Statistical analyses of the DMSO samples as compared to controls were completed using 
an ordinary one-way ANOVA with multiple comparison test (Bonferroni) using Graphpad 
prism 7 software.  
Radiolabeling Hydrogels with [18F]HFB 
[18F]HFB was prepared as previously described (Section 3.2.2.2)  and dissolved in 0.5 
mL of DMSO in 4.5 mL of saline. Radiolabeling of chitosan hydrogels was performed using 
the two approaches described above, this time with [18F]HFB dissolved in the 10% DMSO 
solution. Both methods were compared in terms of loss of radioactivity during mixing steps 
and the efflux of [18F]HFB from the hydrogel when immersed in saline solution at 37˚C.  
Two approaches were utilized to measure the efflux of [18F]HFB from the hydrogels. A 
first set of experiments was conducted using transwells (procedure 1). A volume of 2-3 mL 
of radiolabeled hydrogel was prepared according to approach 1 or 2 and the radioactivity in 
the syringes was measured after each mixing step. The hydrogels were then dispensed in 0.5 
mL portions into 40 µm transwells. The radioactivity in each portion was measured and the 
hydrogels were allowed to gel in 5 mL of saline for 5 min at 37˚C in a hot water bath. An 
additional 10 mL of saline was then added to each hydrogel, to completely cover the gel. The 
efflux of [18F]HFB from the hydrogels was measured at time points of 5 min, 1h, 2h, 4h, 6h 
and 8h by removing the gel from the saline and rinsing with an additional 5 mL of saline. 
The radioactivity was measured in the saline and saline rinses and the labeled hydrogels. All 
data were decay corrected and compared to the initial amount of radioactivity used in the 
respective incubation.  
 The second method involved using gel molds (procedure 2) to measure the efflux of 






approach 1 and 2 and the radioactivity in the syringes was measured after each mixing step.  
The labeled hydrogels were then dispensed into a gel mold (a 10-mL syringe cut into small 
portions with one side covered in parafilm) and allowed to incubate at 37˚C in a cell 
incubator for 2-3 hours to gel. The hydrogel was then carefully removed from the mold and 
placed in a beaker of saline. The efflux of [18F]HFB from the hydrogels was measured at 
time points of 5 min, 1h, 2h, 4h and 6h by removing the gel from the saline and rinsing with 
an additional 5 mL of saline. The radioactivity was measured in the saline and saline rinses. 
The labeled hydrogel molds were placed in a new beaker of saline for the subsequent time 
point. All data were decay corrected and compared to the initial amount of radioactivity used 
in the respective incubation.  
3.3.3.4 Radiolabeling Hydrogels with [18F]F- 
To test the specificity of [18F]HFB to label the chitosan-based hydrogels, a control 
study using only [18F]F- to label the hydrogels was also conducted. Only approach 2 was 
performed for the mixing of the radiolabeled hydrogel replacing [18F]HFB by [18F]F- (for 1 
mL of gel: 0.6 mL of chitosan with 0.35 mL of GA (1.14x BGP) followed by the addition of 
0.05 mL of [18F]F- present in O-18 enriched water (as [18F]HF). The hydrogels were mixed 
using 3 mL syringes connected by a luer lock and the components were passed back and 
forth through the syringes to ensure complete mixing. As above, transwells and gel molds 

























Figure 3.1. Synthetic scheme for the synthesis of the [18F]HFB precursor (4).  











Figure 3.3. The IBA Synthera® automated kit based radiochemistry synthesizer.  


















































































































Figure 3.6. First Exosome labeling strategy. 
























































Figure 3.8. Hydrogel labeling strategy including preliminary study on the effect of DMSO 










     N-hexadecyl-4-(N,N-dimethylamino)benzoate was obtained in a 74% yield as a white 
powder. Melting point: 61-63 oC. 1H NMR (300 MHz, CDCl3) δ 7.90 (d, J = 9.0 Hz 2H), 
6.84 (d, J = 8.5 Hz, 2H), 4.26 (t, J = 6.5 Hz ,2H), 3.06 (s, 6H), 1.80 – 1.68 (m, 2H), 1.50 – 
1.12 (m, 26H), 0.88 (t, J = 6.4 Hz, 3H). HRMS, calculated for [C25H43NO2+ H]
+: 
390.3363, measured: 390.3372. 
4.1.2 Triflate Precursor: Hexadecyl-4-(N,N,N-trimethylamino)benzoate triflate  
 
Hexadecyl-4-(N,N,N-timethylamino) benzoate triflate was obtained in a 98% yield as 
white fluffy powder. HPLC: Luna C8(2) semi-prep column (97:3 MeCN/AF (0.1M), flow: 8 
mL/min: 14.7 min. Melting point: 104-106 oC. 1H NMR (300 MHz, CDCl3) δ 8.25 (d, J = 8.6 
Hz, 2H), 7.92 (d, J = 8.7 Hz, 2H), 4.34 (t, J = 6.7 Hz, 2H), 3.79 (s, 9H), 1.87 – 1.68 (m, 2H), 
1.49 – 1.13 (m, 26H), 0.87 (t, J = 6.4 Hz, 3H). HRMS, calculated for [C26H46O2N] +: 
404.3529, measured: 404.3520. Analytical HPLC retention time (Rt) (Shimadzu C18 (50x4.6 
mm, 5 µm), 95/5 (MeCN/AF (0.1M), 1.5 mL/min) = 14.7 min (Figure 4.1) 
4.1.3 HFB Standard: Hexadecyl-4-fluorobenzoate  
 
Hexadecyl-4-fluorobenzoate was obtained in an 86% yield as a white powder. HPLC: 
Luna C18 analytical column (99:1 MeCN/AF (0.1M), flow: 4 ml/min): 6.01 min. Melting 
point: 43-44 oC. 1H NMR (300 MHz, CDCl3) δ 8.06 (m, 2H), 7.10 (m, 2H), 4.30 (t, J = 6.7 
Hz, 2H), 1.82 – 1.70 (m, 2H), 1.48 – 1.20 (m, 26H), 0.88 (t, J = 6.5 Hz, 3H). HRMS, 






(Rt) (Shimadzu C18 (50x4.6 mm, 5 µm), 95/5 (MeCN/AF (0.1M), 1.5 mL/min) = 6.76 min 
(Figure 4.2)  
4.2 Radiochemistry  
4.2.1 C18 Seppak Experiments  
 
 To remove any unreacted [18F] fluoride, other salts and DMSO prior to going to semi-
prep HPLC purification, the reaction mixture was passed through a C18 Seppak light 
cartridge. The amount of solvent needed to elute HFB (>90%) had to be tested and the 
following results were obtained:  
Table 4.1. Elution experiment 1: 0.5mg HFB and MeCN used as the eluting solvent (collected 
0.5 mL fractions). 
Vial 
 
Solvent Volume HPLC % of HFB eluted 
1 H2O 1 mL ------- ------- 
2 H2O 0.5 mL ------- ------- 
3 H2O 0.5 mL ------- ------- 
4 H2O 0.5 mL ------- ------- 
5 H2O 0.5 mL ------- ------- 
6 MeCN 0.5 mL HFB 0.5% (0.5%) 
7 MeCN 0.5 mL HFB 27% (27.5%) 
8 MeCN 0.5 mL HFB 61% (88.5%) 
9 MeCN 0.5 mL HFB 10% (98.5%) 
10 MeCN 0.5 mL HFB 1.5% (100%)* 



















Table 4.2. Elution experiment 2: 0.5mg HFB and MeCN used as the eluting solvent (collected 1 
mL fractions).  
Vial Solvent Volume HPLC % of HFB eluted 
1 H2O 5 mL ------- ------- 
2 H2O 5 mL ------- ------- 
3 H2O 5 mL ------- ------- 
4 H2O 5 mL ------- ------- 
5 MeCN 1 mL HFB 9% (9%) 
6 MeCN 1 mL HFB 78% (87%) 
7 MeCN 1 mL HFB 13% (100%)* 
8 MeCN 1 mL HFB ------- 
*Percentages represent total amount of HFB eluted from the C18 Seppak light cartridge  
 
Table 4.3. Elution experiment 2: 0.5mg HFB and MeOH used as the eluting solvent (collected 
0.5 mL fractions).  
Vial Solvent Volume HPLC % of HFB eluted 
1 H2O 5 mL ------- ------- 
2 H2O 5 mL ------- ------- 
3 H2O 5 mL ------- ------- 
4 H2O 5 mL ------- ------- 
5 MeOH 0.5 mL HFB 5% (5%) 
6 MeOH 0.5 mL HFB 44% (49%) 
7 MeOH 0.5 mL HFB 31% (80%) 
8 MeOH 0.5 mL HFB 12% (92%) 
9 MeOH 0.5 mL HFB 8% (100%)* 
10 MeOH 0.5 mL HFB ------- 
*Percentages represent total amount of HFB eluted from the C18 Seppak light cartridge  
 
From these experiments, it was concluded that the majority of HFB (>90%) could be eluted 







4.2.2 Radiochemical Results  
 
 For a typical 1hr beam, approximately 1000-1200 mCi was produced and delivered to the 
dispensing hot cell. Once the activity was measured, this was transferred to the Synthera® 
ASU by means of suction via the modules vacuum pump. For test runs of [18F]HFB, shorter 
beams or rinses were used to limit the amount of radioactivity, however, for exosome and 
hydrogel experiments, longer beams with more radioactivity were required. Following 
delivery of the radioactivity to the Synthera® module, the total synthesis time was 
approximately 40 min, followed by a 20 min HPLC purification. The synthesis of [18F]HFB 
took place in one reactor with a 20 minute fluorination step at 100˚C, to produce [18F]HFB in 
a 34% +/- 9%radiochemical yield (RCY, decay-corrected) (~ 330 mCi starting from 1200 
mCi). Following semi-prep HPLC (Retention time (Rt) of [18F]HFB = 18-20 min), the 
solvent was evaporated using a heating block, a vacuum pump and nitrogen gas flow. This 
step took approximately 10 – 15 minutes to completely evaporate all the solvent. Product 
reformulation was completed in approximately 5 minutes, to give a total synthesis time from 
end of beam (EOB) of 1 h 20 minutes, plus another 10 min for quality control by HPLC 
analysis.  
4.2.3 Optimization of fluorination conditions  
 
 Four different fluorination conditions were tested with the goal of maximizing the yield 
of [18F]HFB while minimizing the production of radioactive by-products. The four conditions 
tested were: 100˚C for 30 min, 140˚C for 30 mins, 80˚C for 30 min and 100˚C for 20 min to 









Table 4.4 Effect of fluorination conditions on [18F]HFB purity and yield.  















A 3 100/30 43.3% 83% 36% 
B 3 140/30 36.7% 50% 18% 
C 3 80/30 6.79% 95% 6.45% 
D 3 100/20 33% 97% 32% 
  
Through increasing the fluorination temperature to 140˚C, this produced a higher proportion 
of radioactive by-product (Figure 4.3 B) than when fluorination took place at 100˚C (Figure 
4.3 D). Dropping the fluorination temperature to 80˚C produced highly pure [18F]HFB, 
however, in a very low yield (6.45%) (Figure 4.3 C). 100˚C produced the optimal ratio of 
radiochemical purity and yield.  
4.2.4 Optimization of semi-prep HPLC conditions  
 
 Initial semi-prep HPLC conditions were optimized using a Luna C8(2) column and a 
mobile phase of 97:3 (MeCN/AF (0.1M) at a flow of 10 mL/min to give a retention time of 8 
minutes for [18F]HFB. However, it was noticed that a non-radioactive impurity was co-
eluting with the [18F]HFB radioactivity peak. This peak was identified as a non-radioactive 
impurity and not cold HFB on analytical HPLC using a C18 column, where it was observed 
that there was a UV peak (254 nm) associated to [18F]HFB, followed by a large UV peak 
directly after (Figure 4.4). This second UV peak was lowering the chemical purity of the 






column and the mobile phase switched to 95:5 (MeCN/AF (0.1M) at a flow of 10 mL/min to 
obtain better resolution between the peaks (Figure 4.5). With these conditions, [18F]HFB has 
a Rt of 18 min, along with higher chemical purity (>95%).  
4.2.5 Gas Chromatography of final formulation of [18F]HFB 
 
 The results of the GC analysis of the evaporation experiments completed using HPLC 
solvent and saline to reformulate are summarized as follows: 
Table 4.5 Gas chromatography results of first evaporation experiments: 2 min evaporation.  








time (dryness + 
additional time) 
(min) 
PPM of MeCN 
1 15 120 8 + 2 1207 
2 15 120 9 + 2 850 
3 15 120 10 + 2 132 
4 15 120 10 + 2 176 
 
Table 4.6. Gas chromatography results of second evaporation experiments: 2.5 min evaporation.  








time (dryness + 
additional time) 
(min) 
PPM of MeCN 
1 15 120 8 + 2.5 20 
2 15 120 9 + 2.5 0 
3 15 120 10 + 2.5 0 
 
The addition of an extra 2.5 minutes after dryness in the second experiments (Table 4.6) as 






drastically reduced the ppm of MeCN in the final formulation from an average of 591.25 
ppm to 6.66 ppm.  
4.2.6 Quality Control  
 
 Figure 4.6 demonstrates a typical analytical HPLC obtained for the final formulation of 
[18F]HFB. The identity of [18F]HFB was confirmed by a co-injection of the final formulation 
with the cold standard (Figure 4.7). The chemical and radiochemical purity were consistently 
greater than 98% (after optimization of semi-prep HPLC conditions). Due to the setup of the 
HPLC, the sample flows first through the radiation detector, followed by the UV detector, 
resulting in a small delay between the radiation and UV peak times. The molar activity 
ranged from 46 – 272  mCi/µmol. The amount of residual MeCN in the final formulation was 
consistently below the accepted limit of 410 ppm.  
4.2.7 Exosome Experiments  
4.2.7.1 Exosome Exclusive Spin Columns 
 
 To remove unbound [18F]HFB from labeled exosomes, the first strategy that was 
implemented was the use of exosome exclusive spin columns. The results were the 
following:  
Table 4.7. Radioactivity in eluate and remaining on spin column of exosome exclusive spin 
column tests. 
Centrifugation force/time Activity in eluate (µCi) Activity remaining on spin 
column (µCi) 
750 x g / 2 min 98 (98%) 2 (2%) 
700 x g / 1 min 105 (88%) 15 (12%) 







The majority of the radioactivity eluted through the column, while only a small fraction 
remained on the exosome exclusive spin columns, regardless of the centrifugation conditions. 
Reducing the force from 700 x g to 500 x g resulted in a small increase of radioactivity 
remaining on the column.  
4.2.7.2 PD-10 Column Experiments 
 
 The elution profiles for [18F]HFB in different reformulation conditions are summarized in 
the following figures: 10% DMSO/PSB (Figure 4.8.1), 5% DMSO/PSB (Figure 4.8.2) and 
10% DMSO/PBS + 0.1% Tween (Figure 4.8.3 and  4.8.4). Briefly, the majority of [18F]HFB 
was eluted in the solvent front (0.5 mL – 1.0 mL). The elution volume of [18F]HFB through 
the PD-10 column was slightly increased to 1.0 mL – 2.0 mL with the addition of 0.1% 
Tween in the final formulation and when it was used as the elution solvent (Figure 4.8.3-4).  
4.2.7.3 Exosome Labeling 
 
 As shown in Table 3.1 various radiolabeling conditions were tested for exosomes. The 
results of these experiments are summarized in Tables 4.9.1 - 7. The data is decay corrected 
and the percentages represented are either a percent of activity remaining from the starting 
activity, or from the previous step in the experiment. There was a large proportion of 
[18F]HFB that stuck to the tubes, while this was slightly reduced with the addition of BSA. 
The effect of [18F]HFB sticking to the incubation and centrifugation tubes was further 
increased when both of these were completed at 4˚C. Regardless of the incubation 
temperature or centrifugation conditions, there was no difference in the amount of 
radioactivity in the resuspended exosome sample and the [18F]HFB controls. In certain 
experiments (Table 4.9.5), there was more radioactivity in the resuspended pellet from the 






in sticking of [18F]HFB between the regular Eppendorf tubes and the low retention 
Eppendorf tubes (Table 4.9.3).  
4.2.7.4 ITLC Analysis  
 
 Figure 4.10 A presents the ITLC analysis of a 34 µL sample of exosomes incubated with 
50 µL of [18F]HFB, centrifuged at 200,000 x g for 4 hours and resuspended in 60 µL of PBS 
and Figure 4.10 B is the [18F]HFB control for the same conditions. The retention factor (Rf) 
of [18F]HFB is approximately 0.83 and there was no difference in retention time, or 
appearance of a second radioactive peak in the exosome sample as compared to the [18F]HFB 
control. The same results were obtained for all the labeling conditions.  
4.2.8 Hydrogel Experiments  
4.2.8.1 Effect of 10% DMSO/Saline on hydrogel rheological and mechanical properties 
(Work completed by Yasaman Alinejad). 
 
 First, to verify that labeling would not strongly impact gel rheological and mechanical 
properties, the effect of DMSO on these factors was tested. The effect of adding [18F]HFB 
using approach 1 on the rheological and mechanical properties of hydrogel is summarized in 
Figure 4.11.1. In this method, chitosan was first mixed with DMSO/water (at 0.5%, 1% and 
2% v/v) followed by addition of the GA. As seen in Figure 4.11.1A, addition of DMSO did 
not have a great influence on the kinetics of gelation of the hydrogels at 37° C. However, 
increasing the concentration of DMSO (1% and 2% v/v) had a significant effect on the 
storage modulus of the hydrogels (G’), as measured after 30 min of gelation (Figure 
4.11.1B). A similar trend was obtained with approach 2 (chitosan mixed with DMSO/water 
(0.5%, 1% and 2% v/v), prior to addition of the gelation agent (Figure 4.11.2), however, the 
difference was not large enough to be significant. For the mechanical properties after 24h 






increasing concentration of DMSO for approach 2 (Figure 4.11.3), whereas there was a 
minimal change in the secant modulus for approach 1 (Figure 4.11.4) although no significant 
differences were observed for either approach.  
From these experiments, it was concluded that regardless of the method of mixing, 
DMSO did not present a considerable effect on the rheological properties of the hydrogels 
during gelation at 37˚C, however, a significant difference in the storage modulus was 
observed for increasing concentrations of DMSO (1% and 2%). Therefore, it was 
recommended to formulate the hydrogels with the lowest concentration of DMSO possible 
(0.5% v/v) as to limit the changes in the mechanical properties of the final hydrogel and for 
future studies involving cells that do not tolerate higher concentrations of DMSO.   
4.2.8.2 Hydrogel radiolabeling using [18F]HFB 
 
 During the preparation of the labeled hydrogels, approach 1 resulted in an average loss of 
radioactivity during mixing of 41.2%, whereas approach 2 had an average loss of 
radioactivity during mixing of 16.2% (Figure 4.12.1).  As seen in Figures 4.12.2-5, a similar 
trend is observed in terms of labeling stability, regardless of the approach used to prepare the 
radiolabeled hydrogels for both the transwell experiments and gel molds. After 8 hours, over 
90% of the radioactivity remained in the hydrogel, with a slight efflux of [18F]HFB observed, 
corresponding to a maximum loss of 9%. Due to the higher losses of radioactivity during 
mixing seen with approach 1, approach 2 was solely used going forward. Approach 2 was 
repeated with a larger sample size (n =3) for the transwell experiments and gel molds. The 
transwell experiments involving the same gel for all time points and gel molds displayed an 
identical trend as the previous experiments with over 90% labeling stability after 8 hours 







4.2.8.3 Hydrogel radiolabeling using F-18 
 
 Only approach 2 was utilized to prepare the radiolabeled hydrogels using [18F]F-. As 
observed in Figure 4.13.1, the losses during mixing were very minimal with a 5.5% and 5.1% 
for the transwell gels and molds, respectively. In terms of radiolabeling stability, Figure 4.13.2 
demonstrates that after 5 mins, only 26% of the initial F-18 remains in the gel with the rest in the 
saline rinse. After 1 hour, less than 10% of the F-18 was found in the gel and finally, after 6 
hours, only 3% of the starting F-18 remained in the hydrogel. A similar trend was observed for 
the gel mold experiments, where after 5 mins 39% of the starting F-18 remained in the gel, only 
3% of starting F-18 remained in the gel after 1 hour, while 1% of the radioactivity remained in 
























Figure 4.1.  Analytical HPLC of the HFB standard ((Shimadzu C18 (50x4.6 mm, 5 µm), 95/5 
(MeCN/AF (0.1M), 1.5 mL/min).  
Figure 4.2.  Analytical HPLC of the precursor ((Shimadzu C18 (50x4.6 mm, 5 µm), 95/5 
























































Figure 4.3.  Analytical Rad HPLC of the reaction mixtures (Luna C18, 99:1 (MeCN/AF (0.1M) 4 mL/min): B) 140˚C/30 min, C) 
































0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
Figure 4.4. Analytical HPLC at 254 nm (Luna C18 99/1 (MeCN/AF (0.1M), 4 mL/min) of the final formulation of 
[18F]HFB prior to optimizing semi-prep HPLC purification conditions. A non-radioactive impurity was co-eluting 
with the radioactive peak of [18F]HFB during semi-prep HPLC, while separation of these two peaks was seen on 
analytical HPLC.  
Cold mass of HFB 
































Figure 4.5. Semi-prep HPLC optimization. A) C8(2) column (97:3 MeCN/AF (0.1M), 10 mL/min) 
resulted in co elution of [18F]HFB (Rt = 8 min) with a non-radioactive by-product. B) Resolution was 












































































































0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00
Figure 4.6. Analytical HPLC at 254 nm (Luna C18 99/1 (MeCN/AF (0.1M), 4 mL/min) of the final 































































































Figure 4.7. Analytical HPLC at 254 nm (Luna C18 99/1 (MeCN/AF (0.1M), 4 mL/min) of the final 






















































Figure 4.8.1. Elution profile of 1 mL [18F]HFB in 10% DMSO/Saline  loaded onto a PD-10 
column and eluted using PBS.  
Figure 4.8.2. Elution profile of 1 mL [18F]HFB in 5% DMSO/Saline  loaded onto a  PD-10 






















































Figure 4.8.3. Elution profile of 1 mL [18F]HFB in 10% DMSO/PBS + 0.1% Tween  loaded 
onto a PD-10 column and eluted using PBS.  
Figure 4.8.4. Elution profile of 1 mL [18F]HFB in 10% DMSO/PBS + 0.1% Tween  loaded 












































Table 4.9.3. Exosome radiolabeling results from 21 Dec 2016 (12,000 rpm centrifugation). 
 
 











































Table 4.9.5. Exosome radiolabeling results from 2 Feb 2017 using ultracentrifugation (200,000 x g).   
 
 














Table 4.9.6. Exosome radiolabeling results from 10 Feb 2017 using ultracentrifugation (200,000 
x g).  
 
Percentages represent either a percentage of the starting activity or pellet from the previous step 
Table 4.9.7 Exosome radiolabeling results from 17 Feb 2017 using ultracentrifugation (200,000 
x g). 
 

































Figure 4.10. ITLC analysis of:  A) 34 µl exosomes incubated with 50 µl of [18F]HFB and 
centrifuged at 200,000 x g for 4 hours and resuspended in 60 µl of PBS. B) [18F]HFB. 
control centrifuged at 200,000 x g for 4 hours and resuspended in 60 µl of PBS.  
A B 
Figure 4.11.1. Effect of 0.5%, 1% and 2% DMSO added first to chitosan followed by 
addition of the gelation agent (approach 1) on the (A) evolution of storage (G’) and loss 
(G’’) moduli of hydrogels during gelation at 37°C (mean, n=3) and (B) on G’ value after 30 






























Figure 4.11.2. Effect of 0.5%, 1% and 2% DMSO added following mixing of chitosan and 
the gelation agent (approach 2) on the (A) evolution of storage (G’) and loss (G’’) moduli of 
hydrogels during gelation at 37°C (mean, n=3) and (B) on G’ value after 30 min at 37 °C 
(mean±SD, n=3). 
Figure 4.11.3. Effect of 0.5%, 1% and 2% DMSO added first to chitosan followed by 
addition of the gelation agent (approach 1) on the secant modulus of hydrogels at 50% 























































Figure 4.11.4. Effect of 0.5%, 1% and 2% DMSO added following mixing of chitosan and 
the gelation agent (approach 2) on the on the secant modulus of hydrogels at 50% 
deformation (mean±SD, n=3).  
 
Figure 4.12.1 Percentage of [18F]HFB  lost during the preparation of the radiolabeled hydrogels 



























































Figure 4.12.2. Percentage of [18F]HFB  remaining in labeled hydrogels and saline rinses for 
approach 1: (CH + [18F]HFB) + GA: transwell experiments (procedure 1) (n = 2).  
Figure 4.12.3. Percentage of [18F]HFB remaining in labeled hydrogels and saline rinses for 





















































Figure 4.12.4. Percentage of [18F]HFB  remaining in labeled hydrogels and saline rinses for 
approach 1: (CH + [18F]HFB) + GA: gel mold experiments (procedure 2) (n = 2).  
Figure 4.12.5. Percentage of [18F]HFB remaining in labeled hydrogels and saline rinses for 






















































Figure 4.12.6. Percentage of [18F]HFB remaining in labeled hydrogels and saline rinses for 
approach 2: (CH + GA) + [18F]HFB: transwell experiments (procedure 1), using the same 
sample for each time point (mean±SD, n=3).   
Figure 4.12.7. Percentage of [18F]HFB  remaining in labeled hydrogels and saline rinses for 





























































Figure 4.13.1.  Percentage of F-18 lost due to mixing (approach 2) for the transwell and 
mold experiments.  
Figure 4.13.2. Percentage of F-18 remaining in labeled hydrogels and saline rinses for 









































Figure 4.13.3. Percentage of F-18 remaining in labeled hydrogels and saline rinses for 









Before proceeding with the radiochemistry work, it was necessary to synthesize both the 
[18F]HFB precursor as well as the cold HFB as a standard to confirm the identity of the “hot” 
[18F]HFB product. The synthesis of these compounds was already described in the literature 
[1]. However, modifications were made to the radiosynthesis and purification to adapt the 
synthesis to the Synthera platform. The trimethyl ammonium triflate precursor of [18F]HFB 
(hexadecyl-4-(N,N,N-trimethylamino)benzoate triflate) was prepared in two steps; the first 
step involved the formation of an ester via SN2 substition of a chlorine atom on 4-(N,N-
dimethylamino)benzoyl chloride by the alcohol group of 1-hexadecanol. The reaction 
mixture was purified by column chromatography. The final product was re-crystallized using 
a minimum of hot ethyl acetate for dissolution followed by removal of leftover impurities in 
the solution at room temperature. The second step was the formation of the trimethyl 
ammonium substituted triflate salt using methyl triflate. The addition of the methyl group 
resulted in a quaternary amine which created an ionic bond with the resultant triflate group, 
turning this into a counter for the leaving group, ideal for [18F]F- displacement. The cold 
HFB standard was prepared in a one-step reaction through an SN2 substitution of a chlorine 
on 4-fluorobenzoyl chloride by the alcohol group of 1-hexadecanol, and the reaction mixture 
was purified by flash chromatography. All the compounds were characterized by mass 
spectrometry and 1H-NMR. They all contained a characteristic multiplet that integrated for 
26 protons, belonging to the long lipophilic chain. The purity of the standard was analyzed 
by analytical HPLC and it was >99% (Figure 4.1). The presence of the added methyl group 






total of 9 protons. The overall yields for these reactions were all close to 80% and the triflate 
reaction yield was above 98%.  
HPLC conditions were developed for both the cold HFB standard and the precursor to 
purify the crude reaction mixture and to confirm the identify of hot [18F]HFB. The retention 
time of cold HFB was 6.0 minutes while the precursor had a longer retention time of 14.7 
mins. The large separation time between these two compounds ensure easy purification of the 
precursor from final labeled compound.  
5.2 Radiochemistry 
  
5.2.1 C18 SepPak experiments 
		
When planning the automated radiosynthesis of [18F]HFB using the Synthera® ASU, we 
wanted to ensure the highest purity of the final product and at the same time increase the 
lifespan of the semi-prep HPLC column. Since the fluorination reaction was carried out in 
DMSO - a solvent that can damage HPLC columns overtime and drastically shifts the 
retention time of compounds – removal of DMSO prior to semi-prep HPLC purification was 
done via C18 SepPak elution. The IFP of the Synthera® contains two ports for cartridges 
(Figure 3.5 SepPak positions 1 & 2); the first port is designated for a QMA cartridge for 
[18F]F- trapping, and a second is vacant. C18 SepPaks contain long carbon chains that can 
interact with the long lipophilic chain on [18F]HFB, while unreacted [18F]F- is eluted through 
the cartridge. To implement this purification step into the radiosynthesis of [18F]HFB, it was 
necessary to conduct elution experiments to determine how much volume of solvent will be 
needed to elute [18F]HFB from the cartridge, following water rinses. The C18 SepPak was 
initially conditioned and then loaded with HFB dissolved in DMSO and washed with water 






analyzed via analytical HPLC. From these experiments, it was determined that over 90% of 
HFB could be eluted with a smaller volume of MeCN as compared to MeOH. Considering 
the semi-prep HPLC solvent system consisted of 95% MeCN and AF (0.1M), it was decided 
that MeCN would be more ideal since this would not change the composition/polarity of the 
HPLC solvent system. This system was implemented into the automated synthesis of 
[18F]HFB. However, after the first test run using 2.0 mL of MeCN to elute [18F]HFB, it was 
noticed that a significant amount of radioactivity remained on the C18 cartridge. The volume 
of MeCN was then increased to 4 mL, which was sufficient to remove all the radioactivity 
from the C18 cartridge.  
5.2.2 Optimization of the fluorination conditions  
 
Considering the synthesis of [18F]HFB had never been completed using the Synthera® 
platform, we were interested in optimizing the fluorination conditions to maximize the RCY 
of [18F]HFB, while minimizing the production of radioactive by-products. The reported 
fluorination conditions were 95˚C for 20 mins, therefore, we decided to test 4 different 
conditions: 100˚C/30 mins, 140˚C/30 mins, 80˚C/30 mins and 100˚C for 20 mins. The crude 
reaction mixture was passed through an activated C18 SepPak and eluted with MeCN, 
followed by analytical HPLC to determine the radiochemical purity. The fluorination 
temperature had a drastic impact on the production of a radiochemical by-products that were 
eluted with the solvent front on analytical HPLC. At 140˚C, the radiochemical purity of 
[18F]HFB was only 50%, giving a RCY of approximately 36%. When the reaction 
temperature was reduced to 80˚C, the radiochemical purity was 95%, however, the reaction 
yield was only 6.45%. The radiochemical purity for 100˚C/30 mins and 100˚C/20 mins 






83% with 30 mins. The RCY for the 30-min reactions was only 4% higher than the 20-min 
reaction. Since the radiochemical purity was higher for the 20-min reaction, we decided to 
choose 100˚/20 min for the fluorination conditions. Additionally, the ten-minute difference in 
the radiosynthesis can make a significant impact for the total synthesis time, which should be 
kept to a minimum. In the original manual (not automated) radiosynthesis of [18F]HFB by 
[1], they reached RCYs of 52%, while the highest yield obtained with our automated process 
(Synthera® ASU) was 45% (decay corrected).  
5.2.3 Optimization of semi-prep HPLC conditions 
		
After the first test runs of [18F]HFB, it was noticed that there was a large UV peak that 
was co-eluting with the radioactive peak of [18F]HFB on semi-prep HPLC (Figure 4.5). At 
first, we believed that this was a large mass of unlabeled product, however, when the final 
formulation was analyzed via analytical HPLC, the radioactivity peak of [18F]HFB was 
followed by a large UV peak that did not in fact correspond to the cold mass. The retention 
times of these two peaks were different enough that they could not be associated to one 
compound (Figure 4.4). The difference between the semi-prep and analytical HPLC systems 
was the use of a Luna C8(2) column for semi-prep and a Luna C18 column for analytical 
HPLC. We then substituted the C8(2) semi-prep column for a C18 semi-prep column as this 
would likely provide better resolution between the [18F]HFB radioactive peak and the 
unwanted UV peak. With a solvent system of 95/5 MeCN/AF (0.1M), it was possible to 
obtain enough separation between the [18F]HFB radioactive peak and UV bi-product peak to 
greatly increase the chemical purity of [18F]HFB to > 99%.  
The original Synthera® ASU set-up to go from the IFP module to to HPLC purification 






means that the mixture to inject must be pushed into the loop by means of compressed 
nitrogen and a best guess as to how long it takes for the volume of liquid to reach the loop, 
without under or over-shooting the loop. We were not comfortable with this approach and 
quickly realized this could lead to substantial losses of radioactivity. Consequentially, we 
decided to add an automated syringe driver system to this process. We programmed the 
syringe to suck the eluted C18 SepPak purified reaction mixture and inject this into the loop 
in a two-step process. The loop size was a 5 mL loop, therefore, we had some room for error 
in case a bit of air was pushed into the loop. This proved to be a very effective and 
reproducible loading system for the semi-prep purification.  
5.2.4 Gas Chromatography Analysis 
 
Due to its inherent toxicity, the most recent guidelines for residual solvents set the 
maximum amount of MeCN that should be tolerated in pharmaceutical products at 410 ppm. 
Considering our semi-prep HPLC solvent is composed of 95% MeCN, we had to develop an 
effective protocol to remove MeCN and to ensure that it is present in less than 410 ppm in 
the final formulation of [18F]HFB. The radioactive [18F]HFB peak was collected (Figure 4.5 
– green radioactivity peak) in the dispensing hot cell in our radiochemistry lab, and the 
solvent was evaporated at 120˚C under N2 flow combined with vacuum exhaust. The time of 
evaporation depends on the volume of the peak collected and the typical collected peak 
volumes were approximately 15 mL (10 mL/min flow for 1.5 min). When the solvent was 
evaporated to dryness (+ addition of 2 more min), there was still a significant amount of 
MeCN in the samples, up to three times the allowed limit (Table 4.5). However, when the 






amount of MeCN to well below the accepted limits (Table 4.6). Therefore, this procedure 
was adopted to remove MeCN from the final formulation of [18F]HFB.  
During the evaporation step, there would sometimes be a significant loss of product, 
amounting to 20-30% of the total activity. [18F]HFB has a very long chain and is thus non-
volatile, therefore the loss of product cannot be attributed to evaporation of the product. The 
most likely explanation for the loss of product during evaporation is that some of the product 
is aspirated through the needle that is connected to the vacuum. This needle was always 
placed above the liquid; however, the constant flow of nitrogen could have resulted in some 
of the solvent/product aspired into the needle. To counteract this, the needle was placed just 
below the septum of the [18F]HFB vial and the N2 flow was kept to a minimum.  
5.2.5 Reformulation and Quality control 
			
During the reformulation step of [18F]HFB, it was imperative to work quickly and to keep 
the [18F]HFB/DMSO as warm as possible and to minimize the time spent in syringes during 
transfers. Given that [18F]HFB is a very liphophilic molecule, it sticks to most plastics which 
can result in significant losses of radioactivity and when it cools down to room temperature, 
the solubility of [18F]HFB in DMSO is also decreased due to high concentration of saline 
solution (90%) compared to DMSO. Furthermore, when [18F]HFB was filtered through a 
0.22 µm Acrodisc® filter, this also resulted in significant losses of radioactivity due to 
sticking of the product on the filter. As a result, when very concentrated [18F]HFB was 
needed for exosome and hydrogel labeling, the filtering step was bypassed in order to 
minimize losses of activity in the filter.  
The SA calculated for [18F]HFB was in the range of 46 – 272 mCi/µmol, which is quite 






Ci/µmol [2]. Since we were not targeting a specific receptor that could easily be saturated by 
cold mass, we were not concerned with SA.  The low SA can be attributed to the presence of 
cold HFB in the final formulation of [18F]HFB due to reactivity with F-19 in the various 
tubing. High SA activity was not a goal with this work, changing lines to Tefzel, a 
fluoropolymer that is resilient to radiolysis, and IFP components [3], or beaming for longer 
times to produce more F-18 was not completed for this work.   
5.3 Exosome radiolabeling  
 
When completing a literature review of exosome biodistribution, there are no robust 
studies completed using either fluorescence and optical imaging or PET/SPECT imaging. 
Only one paper can be found on the radiolabeling of exosome mimetic nanovesicles using 
99mTc-HMPAO for SPECT imaging [4]. Our approach for radiolabeling exosomes with 
[18F]HFB was based off this paper, the previous work with [18F]HFB to label CPCs and non-
published reports by the Gibbings lab using fluorescent hydrophobic dyes such as DiR.  
In the paper by Choi et al [4], the use of 99mTc with a half-life of 6 hours allowed for a 1 
hour incubation at room temperature. Working with 18F (half-life of 110 min) limits the time 
available to complete manipulations, therefore, it was determined that a 30-min incubation 
would be tested at three different temperatures: 4˚C, room temperature and 37˚C, as 
completed by Zhang et al [5]to label CPCs. In terms of differences due to temperature in our 
preliminary experiments, it was noticed that there was more radioactivity in the pellet 
following centrifugation in the 4˚C incubation as compared to room temperature and 37˚C 
(Table 4.9.5). At first, we believed this was due to [18F]HFB labeling of exosomes, however, 
after attempting to resuspend the pellet and measure the activity, all of the radioactivity 






that the colder temperatures was reducing the solubility of [18F]HFB to the point where it 
would crash out of solution and end up sticking to the walls of the tubes. We therefore opted 
to incubate the exosomes with [18F]HFB at 37˚C for the subsequent experiments.  
The next challenge was to determine how the radiolabeled exosomes were going to be 
separated from free [18F]HFB. If a purification step is not completed post-incubation in order 
to remove leftover [18F]HFB, it would be impossible to differentiate the signal of the 
radiolabeled exosomes from that of [18F]HFB. This would interfere with the accuracy of the 
biodistribution studies, therefore it was imperative to remove as much free [18F]HFB as 
possible (>95% removal). Choi et al [4] utilised two approaches for removing free 99mTc-
HMPAO from their labeled exosome mimetic vesicles. The first approach was with exosome 
exclusive spin columns (EESC) and the second utilized PD-10 size exclusion columns. Both 
techniques work on the same principle of size exclusion chromatography where larger 
molecules will pass through the column whereas smaller molecules will interact with the 
matrix of the column, leading to a longer elution time (and retention) for these free 
molecules. The EESCs have a molecular weight cutoff of 3000, meaning that molecules 
below this cutoff will interact with the matrix and be retained, whereas molecules above this 
weight will bypass the matrix and be eluted. The EESCs have the disadvantage of having a 
maximum sample loading volume of 100 µL, however, the purification step is very short; 
purified exosomes can be obtained after 2 minutes of centrifugation at 750 x g. The EESCs 
were tested with a 100 µL sample of [18F]HFB spun at 750 x g, 700 x g and 500 x g. The 
eluate was collected and the radioactivity in both the column and eluate was measured. 






instead of being retained in the spin column (Table 4.7). This meant that the EESCs would 
not be an effective way to remove free [18F]HFB from labeled exosomes.  
The PD-10 columns have a higher molecular weight cutoff of 5000 and can tolerate 
larger sample volumes from 1- 2.5 mL. However, they require more time to complete the 
purification step as separation is done via gravity instead of centrifugation for the elution. 
Different formulations of [18F]HFB were tested: 10% DMSO/PBS, 5% DMSO/PBS and 10% 
DMSO/PBS + 0.1% Tween as well as different elution solvents: PBS and PBS + 0.1% 
Tween. As seen in Figures 4.8.1 – 4, the elution profiles of [18F]HFB through the PD-10 
columns were similar for all the conditions. [18F]HFB eluted through the column with the 
solvent front, with the majority of the radioactivity coming out within 0.5 – 1.0 mL. The 
elution volume of [18F]HFB was slightly increased to 1.5 – 2.0 mL with the addition of 0.1% 
Tween. This means that [18F]HFB did not interact with the matrix of the PD-10 columns at 
all and passed directly through the columns, the possible reason for this will be discussed in 
section 5.3.1. In the paper by Choi et al [4], PD-10 columns were utilized to separate free 
99mTc-HMPAO from their labeled exosome mimetic vesicles. The labeled vesicles eluted 
first, while the free 99mTc-HMPAO was retained in the column due to its smaller size. The 
collected fractions were analyzed via ITLC and similar fractions were combined. With this 
approach,  a 99.6% radiochemical purity was obtained in approximately 30 min [4].  Like the 
EESCs, the PD-10 columns were not effective at separating free [18F]HFB from labeled 
exosomes because [18F]HFB was eluting with the solvent front which would have given no 
resolution between labeled exosomes and free [18F]HFB. We then decided to centrifuge to 






Considering the small size of exosomes (30 – 150 nm), it takes an enormous amount of 
force to pellet them. For their purification from cells, a series of sequential centrifugations 
are completed with the longest step consisting of 100,000 x g centrifugation for 2 hours. We 
were limited to using a small bench top centrifuge in the radiochemistry laboratory that had a 
maximum force of 21,000 x g and therefore used this as a starting point. We were also 
limited in time due to the half-life of 18F, therefore we decided to choose a 1 hour 
centrifugation at 21,000 x g. The activity in the supernatant and pellet was measured after 
centrifugation and up to 86% of the initial radioactivity was found in the pellet, however after 
resuspension, all the activity remained stuck to the tube and none was found in the 
resuspension. We believed that at this force of centrifugation, exosomes were not being 
pelleted. After consulting with Dr Mélanie Dieudé (Researcher with expertise in 
exosomes/vesicles) at the CRCHUM, we were told that to fully pellet exosomes requires 18 
hours of centrifugation at 200,000 x g. Based off this, we decided to change our strategy and 
ultracentrifuge at 200,000 x g for up to 4 hours, testing 1h and 2h centrifugations as well. 
With this strategy, the same results were obtained as before: the radioactivity was sticking to 
the tubes and no activity was found in the resuspended pellets. Furthermore, a washing step 
was sometimes completed following centrifugation and a minimum of activity was removed 
with the wash as [18F]HFB was stuck to the tubes.  Consequentially, we decided to test low 
retention Eppendorf tubes which have been shown to reduce the sticking of proteins and 
peptides and improve sample recovery. There was no difference in results between normal 
Eppendorf tubes and the low retention tubes. Finally, there was no difference between the 
control samples of [18F]HFB without exosomes in terms of re-suspended radioactivity (Table 






the controls than in the exosome samples (Table 4.9.3). This confirmed that the radioactivity 
values come from free [18F]HFB and not labeled exosomes and that no labeling of exosomes 
occurred.  
As part of our protocol, we also decided to test different incubation volumes, with the 
lowest volume being 84 µL (34 µL of exosomes + 50 µL of [18F]HFB) and highest volume 
1000 µL (10 µL of exosomes + 990 µL of [18F]HFB). In the paper by Zhang et al [5], it was 
demonstrated that the highest labeling efficiency for CPCs was obtained when the volume of 
[18F]HFB was kept small (1 mL) and the concentration of cells was high (2 x 106 cells/mL). 
Even with 50 µL of [18F]HFB, we were able to reach activities of 1 mCi in the incubation 
which allowed for measurements of activity several hours later. Varying the concentration of 
[18F]HFB and exosomes did not impact the success of radiolabeling. Considering the small 
size of the exosomes, it is quite plausible that the tracer and exosomes did not “interact” with 
each other in solution, this not being the case for CPCs and [18F]HFB. Furthermore, BSA was 
also tested during the incubation of [18F]HFB with exosomes. Firstly, BSA has been 
demonstrated to be a fatty acid transporter across cell membranes [6] and given that 
[18F]HFB resembles a lipid, we hypothesized that BSA may help with uptake of [18F]HFB 
into exosomes. Secondly, BSA has also been shown to reduce the adhesion of proteins to 
reaction tubes, which was a major problem with [18F]HFB. The addition of BSA slightly 
reduced the amount of radioactivity that was stuck to the tubes, however, did not help with 
the radiolabeling of exosomes, as confirmed via ITLC. 
ITLC analysis was completed to verify if the exosomes were labeled or not and this 
approach was inspired by Choi et al [4]. In their paper, they could see a significant difference 






exosomes migrated a short distance on their ITLCs while their free tracer migrated the 
majority of the ITLC plate (Figure 5.1). ITLC conditions were developed for [18F]HFB 
which resulted in an Rf for [18F]HFB of 0.83. Under these conditions, it is expected that 
labeled exosomes would remain at the base line on the ITLC.  Figure 4.10 demonstrates that 
there was no difference in the ITLCs obtained for the exosome samples as compared to the 
[18F]HFB controls. The migration distance of [18F]HFB was slightly changed with the 
addition of BSA, however, only one peak was observed when labeled exosomes would have 
created a second radioactive peak with a much different Rf.  
5.3.1 Limitations with [18F]HFB for exosome labeling  
 
The original developers of [18F]HFB, Ma et al [1], claimed that [18F]HFB was absorbed 
into the membranes of cells, like hydrophobic fluorescent dyes. I hypothesize that that there 
may be a different underlying mechanism by which [18F]HFB labels cells, based off the 
results obtained with the EESCs and PD-10 size exclusion columns. I hypothesize that when 
placed in solution, [18F]HFB forms micelles/liposomes due to its inherent structure. The 
hydrophobic long-chain tail and the slightly more polar head groups align to form a micelle, 
much like a phospholipid bilayer. Consequentially, this “micelle” would greatly increase the 
molecular weight of the [18F]HFB “complex” and possibly explain why were unable to use 
EESCs and PD-10 columns to separate free [18F]HFB from labeled exosomes.  The [18F]HFB 
“complex” could be approximately the same size as exosomes explaining their direct elution 
through these columns. As for the cell labeling, I believe the [18F]HFB micelles were taken 
up by cells through an endocytosis process, rather than being incorporated into membranes, 






exosomes are much smaller than cells and the [18F]HFB micelles could be similar in size to 
exosomes, the same endocytosis process did not take place.  
To overcome the potential production of micelles, we tried adding 0.1% Tween to the 
formulation of [18F]HFB for the PD-10 column tests. Tween is a detergent used to prepare 
stable oil-in-water emulsions and is also used to increase membrane permeability. A similar 
detergent (saponin) was used to render exosome more permeable for loading of catalase for 
treatment of Parkinson’s Disease (PD) in mice [7]. The addition of Tween to the final 
formulation slightly increased the elution volume needed for [18F]HFB to pass through the 
PD-10 columns. Dr. Gibbings was against the idea of using Tween in our exosome 
incubations as it creates large holes in membranes which can greatly affect the 
biodistribution of the exosomes through drastically modifying their surface and can also 
cause exosomes to burst. Whereas in the PD study, the authors were not concerned with 
completing a robust biodistribution study of their exosomes, they simply wanted to 
demonstrate that exosomes could cross the BBB and deliver a large drug which is why 
saponin was used.  
5.3.2 Future directions for radiolabeling exosomes  
 
Although radiolabeling exosomes with [18F]HFB did not prove to be successful, I believe 
it is still a possibility to determine their biodistribution via PET through different strategies. 
Going forward, it would be interesting to try another F-18 based radiotracer that is currently 
being used in the clinic: 14(R,S)-[18F]Fluoro-6-this-heptadecanoic acid ([18F]FTHA). 
[18F]FTHA is an analogue of a long chain fatty acid utilised to measure free-fatty acid uptake 
and oxidation [8]. The same strategy could be applied for [18F]FTHA as for [18F]HFB to 






precursor is commercially available and kits can be ordered from ABX to develop the 
radiosynthesis of [18F]FTHA with our Synthera® ASU which could also be applied in the 
clinic. If this strategy does not work, another strategy could be to label an antibody specific 
to CD63. CD63 is a protein that is found in most exosomes and is used a biomarker to 
identify exosomes [9]. Antibody radiolabeling is an emerging field with many possibilities 
available, and F-18 could either be directly substituted onto the antibody or can be 
incorporated into a chelator for indirect labeling. Finally, another strategy could be to use a 
longer-lived PET radioisotope such as I-124 that has a half-life of 4.18 days. It would be 
possible to develop an I-124 based radiotracer that can be incubated with cells and therefore 
incorporated into exosomes as they are formed. The longer half-life of I-124 would allow for 
this sort of approach (longer incubation and ultracentrifuge time) and the labeled exosomes 
could be easily purified from the cell media using sequential centrifugation.  
5.4 Radiolabeling chitosan-based hydrogels 
 
Before proceeding with the radiolabeling of the chitosan hydrogels, it was first necessary 
to determine the effect of adding DMSO on the gelation kinetics and mechanical properties 
of the gels. This work was completed by an expert in biomaterials, Dr. Yasaman Alinejad 
(postdoctoral fellow in Dr Lerouge’s lab) and her study set the starting point for our hydrogel 
radiolabeling experiments. From these results, it was concluded that if we maintained the 
final concentration of 10% DMSO/saline to 0.5% v/v, the hydrogels would be minimally 
affected (Figures 4.11.1-4). Concentrations above 0.5% v/v of 10% DMSO/saline had a 
significant impact on the storage modulus (approach 1) of the hydrogels, although the secant 
modulus remained unchanged. Another important factor was the sequence of mixing of the 






Gelation agent; or Approach 2 (Chitosan + Gelation agent) + [18F]HFB. The order of mixing 
did not seem to have a large difference in the rheological or mechanical properties of the 
hydrogels, however, after completing some radiolabeling experiments, the order of mixing 
had a large impact on the yield of labeling the hydrogel and on losses of radioactivity. As 
seen with the exosome experiments, [18F]HFB sticks to any plastics and tubes, therefore, it is 
crucial to minimize the amount of transfers involved as to minimize losses of radioactivity. 
When [18F]HFB is mixed with chitosan as a first step as in approach 1, the additional mixing 
step required to add the gelation agent results in losses of radioactivity averaging 42.1%. 
Comparing this to addition of [18F]HFB as a final step, after mixing of chitosan and the 
gelation agent as in approach 2, an average of 16.2 % of activity is lost due to mixing. 
Consequentially, after validating these losses through repeated experiments, we decided to 
forgo approach 1 and solely use approach 2 going forward where [18F]HFB was added in the 
second step.  
With regards to labeling efficiency, Ahmadi et al had observed an 82% efficiency when 
using [18F]HFB to non-covalently label a collagen matrix [10]. With our chitosan 
radiolabeling, > 90% labeling efficiency was observed up until eight hours, where we started 
to see a slight efflux of [18F]HFB thereafter, corresponding to a maximum loss of 
radioactivity of 9%. High labeling efficiency was found, regardless of the order of mixing 
(approach 1 vs. 2) and a similar trend was obtained whether the hydrogels were placed in 
transwells or in molds (Figures 4.12.1-6). We wanted to test the labeling efficiency in both 
the transwells and molds as neither approach represents in vivo conditions perfectly. For the 
transwell experiments, the hydrogel was allowed to gel only for a short period of time before 






allowed to fully gel and form a rigid gel before being submerged in saline. We were worried 
that in a more liquid gel, there may have been a higher efflux of [18F]HFB as compared to the 
mold due to the radiotracer not being as embedded in the gel. This was not the case as there 
was similar labeling stability for the transwell and mold experiments. These experiments 
allowed us to conclude that there was uniform mixing of [18F]HFB throughout the hydrogel 
and that even if the hydrogel is not fully in a “gel state”, the interactions between [18F]HFB 
and the chitosan are strong enough to prevent [18F]HFB from being washed out of the gel. 
We hypothesized that similar results can be expected in vivo.  
To validate the specificity of [18F]HFB for radiolabeling the chitosan-based hydrogels, a 
control was completed with free F-18. The same procedure was followed with F-18, directly 
from the cyclotron, instead of [18F]HFB. As compared to [18F]HFB, there was less F-18 lost 
during the mixing of the hydrogels due to the fact that F-18 does not have the same lipophilic 
properties as [18F]HFB. Considering the hydrogels are largely composed of water and free F-
18 is in the form of a fluoride ion, one would predict that the F-18 would be retained in the 
hydrogel. But this was not the case and a large part of the F-18 was found in the saline rinses 
after just 5 minutes of incubation. After 1 hour of incubation less than 10% of the 
radioactivity remained in the hydrogel for both the transwell experiments and gel molds and 
almost no activity remained after 4 hours. This control validated our strategy to use [18F]HFB 
as a radiolabeling agent for chitosan-based hydrogel and demonstrates that [18F]HFB is an 
excellent radiotracer to be retained within the hydrogel.   
  The only other study completed on radiolabeling chitosan-based hydrogels utilized 
Na131I and they obtained 95% labeling yields with high stability over 6 days [11]. Working 






this study, we are mainly concerned with short term follow up of the localization of our 
chitosan hydrogels after injection in vivo, thus 18F is suitable for our purposes. Moving 
forward, we would like to assess the radiolabeled hydrogel in small animal models. When 
working with the animal models, it will be important to complete a control scan in parallel 
with free [18F]HFB in order to assess its retention in comparison to the labeled biomaterial 
with [18F]HFB. With this, we should be able to account for the approximatively 9% loss of 
































Figure 5.1.  ITLC analysis for radiolabeling of ENVs using [99mTc]-HMPAO and 







The automated synthesis of [18F]HFB was completed using the Synthera® ASU platform. 
Both the fluorination and semi-prep HPLC conditions were optimized to maximize the yield 
and chemical/radiochemical purity of [18F]HFB. [18F]HFB was obtained in 34% +/- 9%  
RCY with > 95% chemical/radiochemical purity within a total synthesis time of 60 minutes. 
The molar activity in the range of 46-190 mCi/µmol at EOS was low, however, we were not 
concerned with this as our target was not a saturable receptor. Various strategies were 
effected for radiolabeling exosomes, including different incubation temperatures, volumes of 
[18F]HFB/exosomes, different centrifugation forces/times and the addition of BSA. However, 
there was no difference between the exosome samples and controls (free [18F]HFB) in 
regards to radioactivity and ITLC analysis. Chitosan-based hydrogels were successfully 
labeled using [18F]HFB with a labeling stability of over 90% even after 8 hours incubated in 
saline, while a control study using free F-18 exhibited less than 10% of the radioactivity 
remaining in the hydrogel after 60 mins. The order of mixing was optimized to add [18F]HFB 
as a final step to minimize losses of radioactivity in the labeling process. [18F]HFB of 
exosomes and biomaterials presents a novel approach to determining their in vivo 
distribution. Work is underway to continue the hydrogel radiolabeling experiments and to 
determine the in vivo safety and efficacy of the hydrogels in animal models. This 
translational work will eventually lead to implementing the use of hydrogels in humans for 
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